phenylalanine has been researched along with nateglinide in 364 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.27) | 18.7374 |
| 1990's | 40 (10.99) | 18.2507 |
| 2000's | 236 (64.84) | 29.6817 |
| 2010's | 85 (23.35) | 24.3611 |
| 2020's | 2 (0.55) | 2.80 |
| Authors | Studies |
|---|---|
| Nishikawa, M; Sato, Y; Shinkai, H; Sukegawa, E | 1 |
| Dan, K; Fukuma, M; Kumashiro, I; Nishikawa, M; Sato, Y; Seto, Y; Shinkai, H; Toi, K; Toyoshima, S | 1 |
| Bakkali-Nadi, A; Malaisse, WJ; Malaisse-Lagae, F | 2 |
| Dan, K; Fujita, T; Hirose, H; Ito, K; Kanda, N; Kato, R; Maruyama, H; Saruta, T; Seto, Y | 1 |
| Akiyoshi, M; Kakei, M; Nakazaki, M; Tanaka, H | 1 |
| Fujitani, S; Yada, T | 1 |
| Dan, K; Hirose, H; Ito, K; Kato, R; Kido, K; Koyama, K; Maruyama, H; Saruta, T; Seto, Y | 1 |
| Dan, K; Fujita, H; Fujita, T; Kato, R; Seto, Y | 1 |
| Akiyoshi, M; Fujitani, S; Ikenoue, T; Maki, T; Yada, T | 1 |
| Brasseur, R; Lins, L; Malaisse, WJ | 1 |
| Fujita, T; Kato, R; Kondo, N; Seto, Y | 1 |
| Au, S; Habucky, K; Karara, A; Labbadia, D; Tse, FL | 1 |
| Kanno, S; Matsuda, K; Ono, I | 2 |
| Malaisse, WJ | 2 |
| Bakkali Nadi, A; Malaisse, WJ; Zhang, TM | 1 |
| Kikuchi, M | 4 |
| Matsuda, K; Mihara, R; Naito, M; Ohtake, R; Ono, I; Suzuki, E; Takesada, H; Tanaka, K; Yatagai, M | 1 |
| Malaisse, WJ; Malaisse-Lagae, F | 1 |
| Fujitani, S; Okazaki, K; Yada, T | 1 |
| Akiyoshi, M; Fujitani, S; Ikenoue, T; Kondo, N; Maki, T; Okazaki, K | 1 |
| Akiyoshi, M; Fujitani, S; Ikenoue, T; Kondo, N; Maki, T; Okazaki, K; Tsuchiya, Y | 1 |
| Jijakli, H; Malaisse, WJ; Ulusoy, S | 1 |
| Kondo, N | 1 |
| Kikuchi, M; Niki, I; Oka, Y; Sakurada, M; Tsukuda, K | 1 |
| Mokuda, O; Morimoto, S; Sakamoto, Y | 1 |
| Meyer, M; Panten, U; Schwanstecher, C; Schwanstecher, M | 1 |
| Fuhlendorff, J; Ladrière, L; Leclercq-Meyer, V; Malaisse, WJ | 1 |
| Malaisse, WJ; Sener, A | 1 |
| Bohov, P; Gasperíková, D; Klimes, I; Líska, B; Mitková, A; Seböková, E; Stanek, J; Ukropec, J | 1 |
| Dunning, BE; Hu, S; Wang, S | 3 |
| Smits, P; Tack, CJ | 1 |
| Bjorkling, F; Ladriere, L; Malaisse, WJ | 1 |
| Bokvist, K; Buschard, K; Gromada, J; Holst, JJ; Hoy, M; Thomsen, MK | 1 |
| Ladrière, L; Laghmich, A; Malaisse, WJ; Malaisse-Lagae, F | 1 |
| Ficková, M; Klimes, I; Macho, L; Seböková, E; Zórad, S | 2 |
| Keilson, L; Mather, S; McLeod, JF; Subramanian, S; Walter, YH | 1 |
| Hashimoto, Y; Inui, K; Saito, H; Sawada, K; Terada, T | 1 |
| Bell, PA; Boettcher, BR; Dunning, BE; Fanelli, B; Geisse, S; Hu, S; Schmitz, R; Wang, S | 1 |
| Clark, PM; Nattrass, M; Smith, JM; Whitelaw, DC | 1 |
| Hashimoto, Y; Inui, K; Saito, H; Uwai, Y | 1 |
| Choudhury, S; Filipek, R; Hirschberg, Y; Lasseter, K; McLeod, JF | 1 |
| Bouter, KP; Dickinson, S; Guitard, C; Hanefeld, M | 1 |
| Hirschberg, Y; Karara, AH; McLeod, JF; Pietri, AO | 1 |
| Garreffa, S; McLeod, JF; Spratt, DI; Walter, YH | 1 |
| Füchtenbusch, M; Schatz, H; Standl, E | 1 |
| Dunn, CJ; Faulds, D | 1 |
| Ikenoue, T; Kondo, N | 1 |
| Clinkingbeard, C; Foley, J; Gatlin, M; Horton, ES; Mallows, S; Shen, S | 1 |
| Landgraf, R | 1 |
| Kalbag, JB; McLeod, JF; Nedelman, JR; Walter, YH | 1 |
| Kawamori, R; Nishiyama, K; Niwa, M; Shimizu, T; Uchino, H | 1 |
| Lieder, TR | 1 |
| Chin, JA; Graham, ED; Mangold, JB; McLeod, JF; Orwig, BA; Rodriguez, LC; Shapiro, MJ; Weaver, ML | 1 |
| de Souza, CJ; Dunning, BE; Lozito, R; Russo, P | 1 |
| Chen, W; de Souza, CJ; Dragonas, N; Gagen, K | 1 |
| Dunning, BE; Foley, JE; Gatlin, MR; Haas, SJ; Hollander, PA; Schwartz, SL; Zheng, H | 1 |
| Gribble, FM; Levy, JC; Manley, SE | 1 |
| Halas, CJ | 1 |
| Dunning, BE; Foley, JE; Pratley, RE | 1 |
| Abe, T; Mori, T; Nagai, Y; Nomura, G | 1 |
| Hu, S; Wang, S | 1 |
| Dunning, BE; Karara, AH; McLeod, JF | 1 |
| Hanif, W; Kumar, S | 1 |
| Anderson, DM; Luzio, SD; Owens, DR | 1 |
| Sternon, J | 1 |
| Gonoi, T; Ichikawa, K; Kusama, H; Seino, S; Shibasaki, T; Sunaga, Y; Yano, H | 1 |
| Baker, DE; Campbell, RK; Levien, TL; White, JR | 1 |
| Dornhorst, A | 1 |
| Devineni, D; Foley, JE; Horowitz, A; Howell, W; Hsu, CH; Kahn, SE; Ligueros-Saylan, M; McLeod, JF; Montgomery, B | 1 |
| Iwamoto, Y; Omori, Y; Takizawa, T; Teno, S; Uto, Y | 1 |
| Yudkin, JS | 1 |
| Nelson, G | 1 |
| Andrews, J | 1 |
| Koivisto, V | 1 |
| Arakawa, Y; Ebihara, S; Hayashi, Y; Kawamura, W; Kikuchi, M; Morita, T; Ogihara, N; Okamoto, M; Okuda, Y; Sakai, T; Takiguchi, K; Uchida, R; Yamaguchi, J | 1 |
| Hu, S | 1 |
| Ahmann, AJ; Riddle, MC | 1 |
| Ball, M; Guitard, C; Marre, M; Usadel, KH; Van Gaal, L; Whatmough, I | 1 |
| Kotapati, S | 1 |
| Bokvist, K; Gotfredsen, CF; Gromada, J; Hansen, BS; Høy, M; Lindström, P; Olsen, HL; Rorsman, P; Thomsen, MK | 1 |
| Foley, JE; Gatlin, MR; Rosenstock, J; Shen, SG | 1 |
| Ashcroft, FM; Carr, RD; Christensen, IT; Hansen, AM; Hansen, JB; Wahl, P | 1 |
| Ball, M; Dickinson, S; Hershon, K; Holmes, D; Saloranta, C | 1 |
| Emoto, A; Koyabu, N; Ohtani, H; Okamura, A; Sawada, Y | 1 |
| Hussar, DA | 1 |
| Davies, MJ | 1 |
| Mori, Y; Sekihara, H | 1 |
| Kikuchi, M; Notoya, Y | 1 |
| Shiba, T | 2 |
| Iguchi, A; Satake, S | 1 |
| Anderson, DM; Buraglio, M; Crick, N; Shelley, S | 2 |
| Ito, S; Kitahara, Y; Mine, T; Miura, K; Takesue, K; Uchida, Y; Wada, R; Yagihashi, S | 1 |
| Kawamori, R; Kitahara, Y; Mine, T; Miura, K; Okano, A | 1 |
| Göke, B; Parhofer, KG | 1 |
| Brunel, P; De Pablos-Velasco, P; Groop, L; Guitard, C; Lahti, K; Pecher, E; Saloranta, C | 1 |
| Caro, J; Salas, M; Ward, A | 1 |
| Courtois, P; Jijakli, H; Ladriere, L; Malaisse, WJ; Oguzhan, B; Sener, A | 1 |
| Astaf'eva, OV; Vinokurova, LV | 1 |
| Chen, W; Lin, KJ; You, QD | 1 |
| Li, G; Su, GQ; Xu, QW; Zhu, CQ | 1 |
| Iizuka, K; Imamura, M; Mori, M; Nagai, T | 1 |
| Chachin, M; Fujita, A; Kurachi, Y; Matsuoka, T; Matsushita, K; Yamada, M | 1 |
| Bauer, S; Brockmöller, J; Kirchheiner, J; Michael, C; Roots, I; Störmer, E | 1 |
| Devineni, D; Lee, JS; McLeod, JF; Prasad, P; Smith, HT; Walter, YH | 1 |
| Hirose, T; Mizuno, R; Yoshimoto, T | 1 |
| Deacon, R; Dunning, BE; Foley, JE; Gutierrez, C; Paladini, S; Valentin, MA | 1 |
| Boettcher, BR; Dunning, BE; Hu, S | 1 |
| Chandrasekharan, S; Desai, A; Ganesan, R; Jain, SD; Jayaram, S; Rao, PP | 1 |
| Birkeland, KI; Bleskestad, IH | 1 |
| Bokvist, K; Buschard, K; Gromada, J; Holst, JJ; Høy, M; Krogsgaard Thomsen, M; Lindström, P | 1 |
| Caminos, QR; Chacín, LF; de la Torre, W; Islas-Andrade, S; López, G; Martínez de Hurtado, E; Revilla-Monsalve, MC; Yupanqui, H | 1 |
| Foley, JE; Fonseca, V; Grunberger, G; Gupta, S; Shen, S | 1 |
| Hale, PM; Hollander, P; Khutoryansky, N; Klaff, L; McGill, J; Raskin, P; South, SA | 1 |
| Del Prato, S; Emmons, RP; Guitard, C; Heine, RJ; Keilson, L; Shen, SG | 1 |
| Backman, JT; Juntti-Patinen, L; Neuvonen, M; Neuvonen, PJ; Niemi, M | 2 |
| Anderson, D; Kellett, N; Marshall, D; Nimmo, W; Shelley, S | 1 |
| Yamada, K | 1 |
| Odawara, M | 1 |
| Sevinc, A | 1 |
| Inoue, T; Itahana, R; Izumi, M; Miyagawa, K; Nakanishi, T; Shibahara, N; Takamitsu, Y | 1 |
| Lehwalder, D; Schandry, R; Schatz, H; Schoppel, K | 1 |
| Bell, PM; Flatt, PR; Lindsay, JR; McKillop, AM; Mooney, MH; O'Harte, FP | 1 |
| Backman, JT; Neuvonen, M; Neuvonen, PJ; Niemi, M | 1 |
| Carroll, MF; Castro, M; Gutierrez, A; Schade, DS; Tsewang, D | 1 |
| Tesz, G; Zawalich, KC; Zawalich, WS | 1 |
| Yoshida, T; Yoshikawa, T; Yoshioka, K | 1 |
| Baron, MA | 1 |
| Bigler, H; Ligueros-Saylan, M; McLeod, J; Prasad, P; Smith, H; Sunkara, G; Wang, Y | 1 |
| Anderson, DM; Barnett, AH; Morgan, R; Owens, DR; Shelley, S | 1 |
| McLeod, JF | 1 |
| Haslbeck, M; Jakob, S; Kellerer, M; Linn, T | 1 |
| Abrahamian, H; Dzien, A; Francesconi, M; Loiskandl, A; Prager, R; Weitgasser, R | 1 |
| Bauer, S; Brockmöller, J; Kirchheiner, J; Meineke, I; Meisel, C; Müller, G; Rohde, W; Roots, I | 1 |
| Kitahara, Y; Miura, K; Mori, Y; Tajima, N | 1 |
| Ferriman, A | 1 |
| Ishida, H; Kadowaki, T; Kawamori, R | 1 |
| Ball, AJ; Flatt, PR; McClenaghan, NH | 3 |
| Brazinsky, SA; Farrell, J; Hale, PM; Hassman, DR; Khutoryansky, N; Madder, RD; Rosenstock, J | 1 |
| Ligueros-Saylan, M; McLeod, J; Prasad, P; Sabia, H; Smith, H; Sunkara, G; Wang, Y | 1 |
| Baron, MA; Foley, JE; Horton, ES; Shen, SG | 1 |
| Boutati, E; Brunel, P; Dimitriadis, G; Lambadiari, V; Maratou, E; Mitrou, P; Raptis, SA | 1 |
| Atkin, SL; Robertson, D; Weaver, JU | 1 |
| Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Kubo, S; Otsuka, Y; Saito, Y; Yamamoto, Y | 1 |
| Higa, N; Shimabukuro, M; Tagawa, T; Takasu, N; Ueda, S | 1 |
| Gall, MA; Lammert, M; Minshall, ME; Nicklasson, L; Palmer, AJ; Roze, S; Spinas, GA; Valentine, WJ | 1 |
| Chen, Y; Qiao, F; Yan, H; Yang, G | 1 |
| Kawamori, R; Miwa, S; Ohmura, C; Tanaka, Y; Watada, H | 1 |
| Baron, MA; Cefalu, W; Fonseca, VA; Gerich, JE; Hsia, S; Kelley, DE; Nestler, JE; Purkayastha, D | 1 |
| Chen, X; He, Z; Liu, X; Zhang, R; Zhao, C; Zhong, D | 1 |
| Kitahara, Y; Mine, T; Miura, K; Mori, Y; Tajima, N | 1 |
| Berney, T; Bosco, D; Carr, RD; Donath, MY; Maedler, K; Zuellig, RA | 1 |
| Blackburn, GL | 1 |
| Hirose, T; Kawamori, R; Nakayama, S; Tanaka, Y; Watada, H | 1 |
| Abletshauser, C; Bengel, FM; Nekolla, SG; Neverve, J; Schnell, O; Schwaiger, M; Standl, E | 1 |
| Mamori, S; Mori, Y; Tajima, N | 1 |
| Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Kubo, S; Okumura, H; Otsuka, Y; Saito, Y | 1 |
| Kuriyama, G; Mori, Y; Tajima, N | 1 |
| Ohyama, Y; Tomono, S; Uchiyama, T | 1 |
| Hirose, T | 3 |
| Tsujii, S | 1 |
| Kawamori, R | 1 |
| Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Kobayashi, Y; Kubo, S; Otsuka, Y | 1 |
| Li, JW; Tian, HM; Wang, JN; Yu, HL; Zhang, XX; Zhao, GZ | 1 |
| Ferrannini, E; Foley, JE; Gastaldelli, A; Mari, A; Pratley, RE | 1 |
| Anastasopoulou, I; Boutati, E; Karafoullidou, A; Karambakalis, N; Katsilambros, N; Kyriaki, D; Lourida, E; Perea, D; Perrea, D; Raptis, SA; Tentolouris, N; Tselepis, AD; Tsoukala, C | 1 |
| Ishimaru, M; Nagawa, H; Suzuki, T; Yamaguchi, H; Yamashita, H; Yamauchi, H | 1 |
| Kanda, K; Kishikawa, H; Okada, Y; Tanaka, Y | 1 |
| Iida, M; Iwase, M; Nakamura, U; Nohara, S; Sasaki, N; Sonoki, K; Uchizono, Y | 1 |
| Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Kobayashi, Y; Okumura, H; Otsuka, Y; Saito, Y | 1 |
| Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Saito, Y | 1 |
| Baron, MA; Gerich, J; Jean-Louis, L; Purkayastha, D; Raskin, P | 1 |
| Campbell, IW | 1 |
| Chen, Y; Yang, G; Yin, J | 1 |
| Gorogawa, S; Hazama, Y; Hori, M; Kaneto, H; Kato, K; Kawamori, D; Matsuhisa, M; Nakamura, Y; Ohtoshi, K; Shiraiwa, T; Yamasaki, Y; Yoshiuchi, K | 1 |
| Abdel-Salam, OM; Baiuomy, AR; El-Batran, SA; Nofal, SM | 1 |
| Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Kubo, S; Saito, Y | 1 |
| Chen, JY; Li, G; Lü, GL; Xu, QW | 1 |
| Desai, M; Huang, WX; Joshi, Y; Tang, Q; Vivilecchia, RV; Yang, R | 1 |
| Groop, LC; Honkanen, EH; Isomaa, B; Sarelin, L; Tuomi, T | 1 |
| Gao, LM; Song, DQ; Yang, P | 1 |
| Makino, C; Ninomiya, N; Okano, A; Orita, H; Sakai, H; Yabuki, A | 1 |
| Hirose, T; Kawamori, R; Kawasumi, M; Kurebayashi, S; Tanaka, Y; Watada, H | 1 |
| Campbell, A | 1 |
| Ai, M; Ogita, K; Shimokado, K; Tanaka, A | 1 |
| Ahrén, B; Axelsen, M; Jansson, PA; Johanson, EH; Sandqvist, M; Schmelz, M; Smith, U | 1 |
| Aoyagi, I; Fujimori, Y; Fuujimori, Y; Itoh, Y; Kojima, M; Kojima, S; Kusama, H; Mori, Y; Ojima, K; Shibata, N; Tajima, N; Yamazaki, Y | 1 |
| Fan, L; Han, CT; He, YJ; Hu, DL; Li, Q; Liu, ZQ; Tan, ZR; Wang, D; Yu, BN; Zhang, W; Zhang, WX; Zhou, HH | 1 |
| Collober-Maugeais, C; Cressier, F; Pecher, E; Ristic, S | 1 |
| Harada, S; Ito, S; Nakaya, Y; Nomura, M | 1 |
| Azuma, K; Daida, H; Fujitani, Y; Hirosea, T; Kawamori, R; Kurokawa, A; Mita, T; Miyauchi, K; Otsuka, A; Tanaka, A; Toyofuku, Y; Watada, H | 1 |
| Mori, Y | 1 |
| Erkent, U; Ertunc, M; Guc, MO; Ilhan, M; Iskit, AB; Onur, R | 1 |
| Chai, J; Hu, QH; Li, HY; Li, MZ; Liang, Z; Luo, GC; Yan, DW | 1 |
| Albrecht, H; Hug, H; Kersten, S; Meyer, UA; Podvinec, M; Roth, A; Rücker, C; Scarsi, M; Schwede, T | 1 |
| Arakawa, M; Hirose, T | 1 |
| Clark, R; Inoue, T; Nagakura, T; Saeki, T; Shinoda, M; Sugaya, Y; Tanaka, I; Yamamoto, E; Yamazaki, K; Yasuda, N | 1 |
| Kanno, Y; Ohno, Y; Suzuki, H; Takenaka, T | 1 |
| Scheen, AJ | 2 |
| Ashwell, SG; Dashora, UK; Home, PD; Sibal, L | 1 |
| Hamasaki, A; Ikeda, H; Inagaki, N; Kawasaki, Y; Kuwamura, N; Nagashima, K; Seino, Y; Takahashi, A; Yamada, Y | 1 |
| Gao, HW; Hong, TP; Lin, YJ; Wang, HN; Xie, C | 1 |
| Mashru, RC; Sankalia, JM; Sankalia, MG; Sutariya, VB | 1 |
| Kaku, K; Katsura, M; Matsuda, M; Ohkuma, S; Shigeto, M | 1 |
| Black, C; Donnelly, P; McIntyre, L; Royle, PL; Shepherd, JP; Thomas, S | 1 |
| Bieger, S; Kühner, P; Quast, U; Stephan, D; Winkler, M; Wolff, F | 1 |
| Jadhav, AS; Pathare, DB; Shingare, MS | 1 |
| Duffy, NA; Flatt, PR; Gault, VA; Green, BD; Irwin, N; McKillop, AM; O'Harte, FP | 1 |
| Collober-Maugeais, C; Cressier, F; Pecher, E; Ristic, S; Tang, P | 1 |
| Huang, L; Li, J; Li, Q; Li, Y; Liang, J; Liu, Y; Luo, R; Ni, Z; Tian, H; Wang, N; Wu, T; Yu, H | 1 |
| Keshetty, S; Maddi, S; Mohan Ega, C; Scriba, GK; Yamasani, MR | 1 |
| Daniilides, K; Gennimata, D; Gikas, E; Kazanis, M; Malli, D; Panderi, I; Vavagiannis, A | 1 |
| Choi, JB; Hirose, T; Kawamori, R; Mita, T; Sato, F; Shimizu, T; Tamura, Y; Tanaka, Y; Watada, H; Watanabe, T | 1 |
| Layton, D; Shakir, SA; Twaites, B; Wilton, LV | 1 |
| Baron, MA; Gerich, JE; Jean-Louis, L; Marcellari, A; Purkayastha, D; Schwarz, SL | 1 |
| Kajioka, T; Kitahara, Y; Miura, K; Yamagishi, S | 1 |
| Bryant, SM; Sherk, DK | 1 |
| Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Gravina, A; Salvadeo, S | 2 |
| Atsumi, Y; Funae, O; Kawai, T; Nakamura, Y; Oikawa, Y; Shimada, A; Suzuki, R; Watanabe, M; Yajima, K; Yamada, S | 1 |
| Kajioka, T; Kitahara, Y; Mine, T; Miura, K | 1 |
| Koizumi, T; Mihara, R; Okudaira, K; Takanohashi, T | 1 |
| Kalliokoski, A; Neuvonen, M; Neuvonen, PJ; Niemi, M | 1 |
| Katsilambros, N; Tentolouris, N; Voulgari, C | 1 |
| Akimoto, Y; Aoyagi, K; Kawai, J; Kawakami, H; Kawamori, R; Matsushima, S; Nagamatsu, S; Nakamichi, Y; Ohara-Imaizumi, M; Okamura, T; Watada, H; Watanabe, T | 1 |
| González-Clemente, JM | 1 |
| Kapoor, JR | 1 |
| Kumar, VV; Potharaju, S; Sabapathi, SK; Satheeshmanikandan, TR; Shraddha, R; Sivakumar, SP; Sridhar, V; Varanasi, KK | 1 |
| Chen, L; Ding, GX; Guo, Y; Hou, WK; Hu, GL; Ji, QH; Li, QF; Li, YX; Luo, R; Wang, H; Wang, PN; Wang, SJ; Zhang, NY; Zhang, YP | 1 |
| Fujii, M; Inoguchi, T; Kobayashi, K; Maeda, Y; Morinaga, H; Nomura, M; Sasaki, S; Sawada, F; Takayanagi, R; Tsubouchi, H | 1 |
| Basu, SK; Rajendran, A | 1 |
| Akimoto, Y; Kawakami, H; Nagamatsu, S; Ohara-Imaizumi, M; Sawada, H | 1 |
| Christiansen, B; Dominguez, H; Hermann, TS; Ihlemann, N; Kveiborg, B; Køber, L; Major-Pedersen, A; Nielsen, D; Rask-Madsen, C; Svendsen, OL; Torp-Pedersen, C | 1 |
| Asano, T; Doi, Y; Iida, M; Iino, K; Iwase, M | 1 |
| Backman, JT; Kalliokoski, A; Neuvonen, PJ; Niemi, M | 1 |
| Bethel, M; Boolell, M; Califf, RM; Duggal, A; Haffner, SM; Holman, RR; McMurray, J | 1 |
| Li, C; Wang, L; Wang, S; Xia, J; Zhang, G | 1 |
| Baron, MA; Israel, MK; Istvan, E | 1 |
| Kawashima, Y; Kudo, N; Shiba, S; Tamura, M | 1 |
| Juurinen, L; Kauppinen-Mäkelin, R; Kock, T; Kotronen, A; Lanki, H; Leppävuori, E; Nikkilä, K; Saltevo, J; Teikari-Myyrä, T; Tiikkainen, M; Yki-Järvinen, H | 1 |
| Cornelius, V; Kasliwal, R; Shakir, SA; Vlckova, V; Wilton, L | 1 |
| Inagaki, N; Nagashima, K | 1 |
| Berbenni, V; Bruni, G; Cardini, A; Girella, A; Lanfranconi, S; Marini, A; Milanese, C; Viganò, E | 1 |
| Gao, X; Gao, Y; Li, GW; Liu, X; Pan, CY; Zhu, XX | 1 |
| Davis, SN | 1 |
| Buse, JB; Einhorn, D | 1 |
| Makino, C; Okano, A; Sakai, H; Yabuki, A | 1 |
| Arai, T; Honjo, T; Ishioka, K; Lee, P; Miki, Y; Mizutani, H; Mori, A; Nishimaki, Y; Oda, H; Saeki, K; Sako, T; Yamashita, T | 1 |
| Bell, PM; Duffy, NA; Flatt, PR; Green, BD; Lindsay, JR; McKillop, AM; O'Harte, FP; Patterson, S | 1 |
| Itagaki, S | 1 |
| Berbenni, V; Bruni, G; Cardini, A; Girella, A; Lanfranconi, S; Marini, A; Milanese, C | 2 |
| Aoyagi, K; Nagamatsu, S; Nakamichi, Y; Nishiwaki, C; Ohara-Imaizumi, M | 1 |
| Longo, R | 1 |
| Bethel, MA; Califf, RM; Gerlock, T; Haffner, SM; Holman, RR; Holzhauer, B; Horton, E; Krum, H; McMurray, JJ; Zuurman, L | 1 |
| Nathan, DM | 1 |
| Belenkov, Y; Bethel, MA; Boolell, M; Buckley, BM; Buse, JB; Califf, RM; Chacra, AR; Charbonnel, B; Chiang, FT; Chow, CC; Davies, MJ; Deedwania, P; Diem, P; Einhorn, D; Fonseca, V; Fulcher, GR; Gaciong, Z; Gaztambide, S; Giles, T; Haffner, SM; Holman, RR; Holzhauer, B; Horton, E; Hua, TA; Ilkova, H; Jenssen, T; Kahn, SE; Krum, H; Laakso, M; Leiter, LA; Levitt, NS; Mareev, V; Martinez, F; Masson, C; Mazzone, T; McMurray, JJ; Meaney, E; Nesto, R; Pan, C; Prager, R; Raptis, SA; Rutten, GE; Sandstroem, H; Schaper, F; Scheen, A; Schmitz, O; Sinay, I; Soska, V; Stender, S; Tamás, G; Tognoni, G; Tuomilehto, J; Villamil, AS; Vozár, J | 2 |
| Inoue, T; Kato, T; Node, K | 1 |
| Kalliokoski, A; Neuvonen, PJ; Niemi, M | 1 |
| Hayashi, M; Kubo, S; Mihara, R; Nakayama, A; Takanohashi, T | 1 |
| Kitahara, Y; Miura, K; Yamagishi, S | 1 |
| Kang, W; Kim, Y; Park, K | 1 |
| Makino, C; Sakai, H; Yabuki, A | 1 |
| Mathew, AJ; Priyadarshini, SM; Raj, NN; Sugappriya, M | 1 |
| Kajioka, T; Kitahara, Y; Miura, K; Takeuchi, M; Yamagishi, S | 1 |
| Gosmanov, AR; Umpierrez, GE; Westerhaus, B | 1 |
| Choi, SH; Kim, DJ; Kim, KH; Lee, YJ; Nguyen, NH; Phan, TD | 1 |
| Bell, PM; Cuthbertson, J; O'Harte, FP; Patterson, S | 1 |
| Bellomo Damato, A; Giorgino, F; Giorgino, R; Laviola, L; Stefanelli, G | 1 |
| Chung, HS; Jun, HJ; Kim, MK; Kim, TK; Ko, JH; Kwon, MJ; Lee, SH; Oh, MK; Park, JH; Rhee, BD; Suk, JH; Yoon, CS | 1 |
| Eto, Y; Kawanabe, H; Kitahara, Y; Miura, K; Ogawa, S; Yasuda, R | 1 |
| Blanco, H; Góõmez, MP; Laguna, JJ; Rojas, P; Sánchez, L; Santos, A | 1 |
| Acharya, S; Nath, LK; Pani, NR | 1 |
| Maddi, S; Scriba, G; Yamsani, MR | 1 |
| Hirose, T; Kudo, K | 1 |
| Grunberger, G | 1 |
| Guo, H; Li, L; Li, Z; Liao, Y; Liu, H; Pan, H; Yan, X; Yang, G; Yang, M | 1 |
| Abdelmoneim, AS; Brocks, DR; Hasenbank, SE; Light, PE; Seubert, JM; Simpson, SH | 1 |
| Arisaka, H; Hayashi, M; Takanohashi, T; Ubukata, K; Yamada, Y | 1 |
| Busse, R; Kreis, J | 1 |
| Fatehi, M; Lang, VY; Light, PE | 1 |
| Arisaka, H; Kubo, S; Shinkai, K; Takanohashi, T; Ubukata, K | 1 |
| Kataoka, Y; Kimura, K; Kosuge, M; Miyamoto, Y; Miyazaki, S; Sase, K; Yasuda, S; Yoshimasa, Y | 2 |
| Masuzaki, H; Sata, M; Shimabukuro, M | 1 |
| Bansal, AK; Dantuluri, AK; Kumar, L; Upadhyay, P | 1 |
| Jivani, NP; Patel, KM; Patel, MM; Satish, CS; Vaghani, SS | 1 |
| Chen, J; Hu, Y; Ma, J; Yu, C; Yuan, L; Zhang, Q; Zhu, Y; Zou, J | 1 |
| Bommineni, MR; Mullangi, R; Nadipelli, M; Sama, V; Yenumula, P | 1 |
| Mita, T; Watada, H | 1 |
| Chen, Y; Cheng, Y; Fan, L; Wang, G; Zhang, W; Zhou, HH | 1 |
| Bhardwaj, A; Chen, TY; Huang, Z; Kaur, J; Knaus, EE; Narang, D; Plane, F | 1 |
| Chen, M; Guo, Z; Hao, J; Houze, J; Lin, DC; Lopez, E; Luo, J; Ma, Z; Nguyen, K; Rulifson, IC; Tian, B; Tian, L; Tran, T; Wang, Y; Zhang, Y | 1 |
| Kaleemuddin, M; Srinivas, P | 1 |
| Wang, L; Yang, JK | 1 |
| Califf, RM; Giles, T; Haffner, SM; Hernandez, AF; Krum, H; Leiter, LA; Martinez, FA; Mazzone, T; McMurray, JJ; Rutten, GE; Standl, E; Sun, JL; Thomas, L; Tognoni, G; Wong, YW | 1 |
| Brancati, FL; Califf, RM; Chatterjee, R; Edelman, D; Svetkey, L; Thomas, L | 1 |
| Anderwald, CH; Bernroider, E; Brehm, A; Krebs, M; Krssak, M; Nowotny, P; Phielix, E; Roden, M; Schmid, AI | 1 |
| Bao, Y; Jia, W; Li, H; Mo, Y; Peng, Y; Zhang, X; Zhou, J | 1 |
| Bruni, G; Canobbio, A; Cardini, A; Conte, U; Maggi, L; Maietta, M | 2 |
| Califf, RM; Chiang, FT; Giles, TD; Haffner, SM; Holman, RR; Mazzone, T; McMurray, JJ; Preiss, D; Rutten, GE; Standl, E; Sun, JL; Thomas, LE; Tognoni, G | 1 |
| Kobayashi, Y; Kohyama, N; Ohbayashi, M; Shiokawa, H; Yamamoto, T | 1 |
| Katsiki, N; Kolovou, G | 1 |
| Bethel, MA; Califf, RM; Chang, F; Disertori, M; Giles, TD; Haffner, SM; Holman, RR; Latini, R; Maggioni, AP; McMurray, JJ; Rutten, GE; Standl, E; Staszewsky, L; Sun, JL; Thomas, L; Tognoni, G | 1 |
| Asad, M; Bashir, S; Khan, H; Nazir, I; Qamar, S; ul Hassnain, F | 1 |
| Kim, SS; Koide, M; Nagasawa, Y; Sawada, T; Shiotani, H; Terashita, D; Yokoyama, M | 1 |
| Chino, Y; Goto, D; Hayashi, T; Ito, S; Kondo, Y; Matsumoto, I; Ogishima, H; Sugihara, M; Sumida, T | 1 |
| Bethel, MA; Califf, RM; Charbonnel, B; Diem, P; Haffner, SM; Holman, R; Horton, ES; Krum, H; Leiter, LA; Mareev, V; McMurray, JJ; Reyes, EM; Schaper, F; Shah, BR; Shen, L; Soska, V; Sun, JL; Thomas, L; Wojdyla, D | 1 |
| Breitschaft, A; Darstein, C; Golor, G; Hermosillo Reséndiz, K; Hu, K | 1 |
| Bales, CW; Bethel, MA; Califf, RM; Davies, MJ; Haffner, SM; Holman, RR; Huffman, KM; Kraus, WE; McMurray, JJ; Sun, JL; Thomas, L; Tuomilehto, J; Yates, T | 1 |
| Nath, LK; Pani, NR | 1 |
| Jung, JS; Kim, CH; Kim, SJ; Kim, SS; Lim, SM; Park, SH; Sim, YB; Suh, HW | 1 |
| Biswas, N; Guha, A; Kuotsu, K; Sahoo, RK | 1 |
| Izumi, S; Komori, T; Kusuhara, H; Maeda, K; Nozaki, Y; Sugiyama, Y; Takenaka, O | 1 |
| Califf, RM; Katz, M; Lopes, RD; McMurray, JJ; Sun, JL; Thomas, L | 1 |
| Chen, M; Hu, C; Jia, W | 1 |
| Hayashi, A; Kubota, M; Nakayama, H; Okamura, M | 1 |
| Bao, Y; Deng, Z; Jia, W; Li, H; Lu, J; Mo, Y; Peng, Y; Zhang, X; Zhou, J | 1 |
| Nakashima, E | 1 |
| Bales, CW; Bethel, MA; Califf, RM; Davies, MJ; Haffner, SM; Holman, RR; Huffman, KM; Kraus, WE; McMurray, JJ; Preiss, D; Schulte, PJ; Thomas, L; Tuomilehto, J; Yates, T | 1 |
| DeFronzo, RA; Ferrannini, E | 1 |
| Fukase, H; Harigai, M; Iida, S; Ikeda, S; Kasahara, N; Miyata, K; Ohba, Y; Saito, T; Takano, Y; Terao, K | 1 |
| Califf, RM; Davies, MJ; Gill, JM; Haffner, SM; Holman, RR; Kraus, WE; McMurray, JJ; Preiss, D; Thomas, LE; Wojdyla, DM; Yates, T | 1 |
| Gaud, R; Wairkar, S | 1 |
| Arisawa, K; Ide, N; Kagawa, Y; Maeda, T; Ogura, K | 1 |
| Deng, C; Dong, Y; Meng, M; Song, Z; Tong, Z; Wang, J; Wang, Y; Xi, R; Yin, Y; Zhang, J; Zheng, L | 1 |
| Hemmingsen, B; Metzendorf, MI; Richter, B; Sonne, DP | 1 |
| Harumi Higuchi Dos Santos, M; Holman, RR; Lopes, RD; McMurray, JJ; Pieper, K; Sharma, A; Sun, JL | 1 |
| Bilker, WB; Brensinger, CM; Chiang, C; Han, X; Hennessy, S; Leonard, CE; Li, L | 1 |
| Gaud, R; Jadhav, N; Wairkar, S | 1 |
| Subudhi, BB; Swain, RP | 1 |
| Adachi, T; Fukase, K; Ito, J; Katagiri, T; Kitagawa, M; Ohta, I; Yamanaka, Y | 1 |
| Alrokayan, SA; Hussain, T; Kutala, VK; Naushad, SM | 1 |
| Chen, L; Chen, T; Hu, J; Hua, Z; Li, S; Li, Y; Wu, D; Xu, Y; Yan, H; Zhao, R | 1 |
61 review(s) available for phenylalanine and nateglinide
| Article | Year |
|---|---|
Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
Topics: Administration, Oral; Biological Availability; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Intestinal Absorption; Molecular Structure; Nateglinide; Phenylalanine; Piperidines; Reference Values; Stereoisomerism | 1996 |
[Preclinical studies of AY4166 (A-4166)].
Topics: Animals; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Nateglinide; Phenylalanine | 1997 |
[Clinical trial of AY4166].
Topics: Clinical Trials, Phase II as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Eating; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Nateglinide; Phenylalanine; Time Factors | 1997 |
[Non-SU, insulin secretagogues].
Topics: Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Indoles; Isoindoles; Nateglinide; Phenylalanine | 1999 |
New drugs for diabetes.
Topics: Carbamates; Chromans; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Nateglinide; Phenylalanine; Piperidines; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Nateglinide.
Topics: Administration, Oral; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypercalcemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Nateglinide; Pancreas; Phenylalanine | 2000 |
[Pharmacological properties of nateglinide, rapid-onset/short-duration insulinotropic agent, in the treatment of type 2 diabetes].
Topics: Animals; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Nateglinide; Phenylalanine | 2000 |
Meglitinide analogues in the treatment of type 2 diabetes mellitus.
Topics: Benzamides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Molecular Structure; Nateglinide; Phenylalanine; Piperidines | 2000 |
Nateglinide.
Topics: Biological Availability; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Administration Schedule; Half-Life; Humans; Hypoglycemic Agents; Male; Nateglinide; Phenylalanine; Randomized Controlled Trials as Topic | 2001 |
Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control.
Topics: Animals; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Glucose; Guanidines; Humans; Hypoglycemic Agents; Indoles; Insulin; Insulin Secretion; Isoindoles; Nateglinide; Phenylalanine; Piperidines | 2001 |
Nateglinide: a new rapid-acting insulinotropic agent.
Topics: Animals; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Guidelines as Topic; Humans; Hyperglycemia; Hypoglycemic Agents; Metformin; Microcirculation; Molecular Structure; Nateglinide; Phenylalanine; Postprandial Period | 2001 |
[New drugs].
Topics: Amdinocillin; Carbamates; Clopidogrel; Cyclohexanes; Drug Interactions; Humans; Hypoglycemic Agents; Nateglinide; Patient Selection; Penicillins; Phenylalanine; Piperidines; Platelet Aggregation Inhibitors; Pneumococcal Vaccines; Raloxifene Hydrochloride; Safety; Selective Estrogen Receptor Modulators; Ticlopidine | 2001 |
Nateglinide therapy for type 2 diabetes mellitus.
Topics: Animals; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine | 2001 |
Insulinotropic meglitinide analogues.
Topics: Adult; Animals; Benzamides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Nateglinide; Phenylalanine; Piperidines; Rats | 2001 |
Restoring post-prandial insulin release in type 2 diabetes.
Topics: Blood Glucose; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Nateglinide; Phenylalanine; Postprandial Period | 2002 |
[Insulin analogs and new oral antidiabetic drugs].
Topics: Administration, Oral; Carbamates; Cyclohexanes; Diabetes Mellitus; Dose-Response Relationship, Drug; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Nateglinide; Phenylalanine; Piperidines; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 1999 |
Current oral agents for type 2 diabetes. Many options, but which to choose when?
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Therapy, Combination; Glycoside Hydrolases; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Piperidines; Receptors, Cytoplasmic and Nuclear; Sulfonylurea Compounds; Transcription Factors | 2002 |
Nateglinide, a new agent for postprandial glucose control in type 2 diabetes.
Topics: Blood Glucose; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine | 2002 |
Insulin secretagogues.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Nateglinide; Phenylalanine; Piperidines; Postprandial Period; Sulfonylurea Compounds; United Kingdom | 2002 |
[Adverse effects of oral hypoglycemic agents].
Topics: Acarbose; Administration, Oral; Biguanides; Cyclohexanes; Drug Interactions; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Nateglinide; Phenylalanine; Pioglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2002 |
[Structures and mechanisms for non SU insulin secretagogues].
Topics: Adenosine Triphosphate; Animals; ATP-Binding Cassette Transporters; Calcium Channels; Carbamates; Cyclohexanes; Exocytosis; Humans; Hypoglycemic Agents; Indoles; Insulin; Insulin Secretion; Islets of Langerhans; Isoindoles; Nateglinide; Organ Specificity; Phenylalanine; Piperidines; Potassium Channels; Potassium Channels, Inwardly Rectifying; Receptors, Drug; Sulfonylurea Receptors | 2002 |
[Nateglinide].
Topics: Animals; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Nateglinide; Phenylalanine | 2002 |
[Metformin--its regimen and effects].
Topics: Acarbose; Biguanides; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Nateglinide; Patient Selection; Phenylalanine; Sulfonylurea Compounds; Treatment Outcome | 2002 |
[Management guideline for elderly diabetic patients].
Topics: Aged; Cyclohexanes; Diabetes Mellitus; Diet, Diabetic; Exercise Therapy; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Metformin; Nateglinide; Phenylalanine; Practice Guidelines as Topic; Sulfonylurea Compounds | 2002 |
The mechanisms underlying the unique pharmacodynamics of nateglinide.
Topics: Adenosine Triphosphate; ATP-Binding Cassette Transporters; Cyclohexanes; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Ion Channel Gating; Islets of Langerhans; Kinetics; Nateglinide; Phenylalanine; Potassium Channels; Potassium Channels, Inwardly Rectifying; Receptors, Drug; Sulfonylurea Receptors | 2003 |
Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis.
Topics: Aged; Blood Glucose; Body Mass Index; Comorbidity; Cyclohexanes; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Randomized Controlled Trials as Topic; Retrospective Studies | 2003 |
[Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus].
Topics: Acarbose; Cyclohexanes; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypertension; Hypoglycemic Agents; Inositol; Insulin Resistance; Nateglinide; Obesity; Phenylalanine; Postprandial Period | 2003 |
[Nateglinide and mitiglinide].
Topics: Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hyperglycemia; Hypoglycemic Agents; Indoles; Insulin; Insulin Resistance; Insulin Secretion; Isoindoles; Metformin; Nateglinide; Phenylalanine; Postprandial Period; Stimulation, Chemical | 2003 |
[symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes?
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Piperidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.
Topics: Area Under Curve; Biological Availability; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Interactions; Food; Half-Life; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liver; Metabolic Clearance Rate; Nateglinide; Phenylalanine; Protein Binding; Structure-Activity Relationship; Tissue Distribution | 2004 |
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Carbamates; Contraindications; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Fasting; Follow-Up Studies; Germany; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Imino Pyranoses; Insulin; Metformin; Middle Aged; Nateglinide; Obesity; Patient Compliance; Phenylalanine; Pioglitazone; Piperidines; Practice Guidelines as Topic; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2003 |
[Pathophysiological conditions progressing from impaired glucose tolerance: coronary artery disease (ischemic heart disease)].
Topics: Acarbose; Cyclohexanes; Fasting; Glucose Intolerance; Glycation End Products, Advanced; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Life Style; Myocardial Ischemia; Nateglinide; Phenylalanine; Pioglitazone; Postprandial Period; Protein Kinase C; Thiazolidinediones | 2005 |
[Effects of nateglinide in impaired glucose tolerance subjects].
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Nateglinide; Obesity; Phenylalanine; Postprandial Period; Risk Factors | 2005 |
[NAVIGATOR trial (nateglinide)].
Topics: Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Endpoint Determination; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Life Style; Nateglinide; Phenylalanine; Primary Prevention; Randomized Controlled Trials as Topic; Risk | 2005 |
[Therapies for newly-onset diabetic patients].
Topics: Acarbose; Cyclohexanes; Diabetes Mellitus, Type 2; Diet Therapy; Enzyme Inhibitors; Exercise Therapy; Glucose; Glucose Intolerance; Glycogen; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Metformin; Nateglinide; Phenylalanine; Sulfonylurea Compounds; Thiazolidinediones | 2005 |
Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus.
Topics: Animals; Benzamides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Piperidines | 2003 |
Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Nateglinide; Phenylalanine | 2005 |
[Significance of insulin secretion pattern lectured by "glinides" in the treatment of postprandial hyperglycemia].
Topics: Cyclohexanes; Diabetes Mellitus, Type 2; Eating; Humans; Hyperglycemia; Hypoglycemic Agents; Indoles; Insulin; Insulin Secretion; Isoindoles; Nateglinide; Phenylalanine | 2005 |
Glycaemic control in type 2 diabetes.
Topics: Adult; Blood Glucose; Blood Glucose Self-Monitoring; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Nateglinide; Patient Education as Topic; Phenylalanine; Sulfonylurea Compounds | 2005 |
[Postprandial hypoglycemia].
Topics: Acarbose; Cyclohexanes; Diet, Carbohydrate-Restricted; Dietary Fiber; Dumping Syndrome; Enzyme Inhibitors; Gastrectomy; Glucose Intolerance; Glucose Tolerance Test; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Nateglinide; Phenylalanine; Weight Loss | 2006 |
[Glinide(s), sulfonylurea(s)].
Topics: Arteriosclerosis; Cardiovascular Diseases; Cyclohexanes; Diabetic Angiopathies; Glucose Intolerance; Hyperglycemia; Hypoglycemic Agents; Indoles; Insulin; Insulin Secretion; Isoindoles; Nateglinide; Phenylalanine; Postprandial Period; Risk Factors; Sulfonylurea Compounds | 2006 |
Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
Topics: Anti-Bacterial Agents; Area Under Curve; Biological Availability; Biotransformation; Carbamates; Cyclohexanes; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Fasting; Food-Drug Interactions; Humans; Hypoglycemic Agents; Intestinal Absorption; Nateglinide; Phenylalanine; Piperidines; Postprandial Period | 2007 |
Meglitinide analogues for type 2 diabetes mellitus.
Topics: Benzamides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Piperidines; Randomized Controlled Trials as Topic | 2007 |
[Sulfonylureas and glinides].
Topics: Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Nateglinide; Phenylalanine; Sulfonylurea Compounds | 2006 |
A review of nateglinide in the management of patients with type 2 diabetes.
Topics: Cyclohexanes; Diabetes Mellitus, Type 2; Fasting; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; KATP Channels; Nateglinide; Phenotype; Phenylalanine; Postprandial Period | 2007 |
Drugs for type 2 diabetes.
Topics: alpha-Galactosidase; Biguanides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Nateglinide; Phenylalanine; Piperidines; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles | 2008 |
Nateglinide versus repaglinide for type 2 diabetes mellitus in China.
Topics: Carbamates; China; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Piperidines | 2009 |
Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes.
Topics: Blood Glucose; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Treatment Outcome | 2008 |
[Progress in therapy for diabetes mellitus--insulin-secretion inducing oral hypoglycemic agents].
Topics: Administration, Oral; Cyclohexanes; Diabetes Mellitus; Glyburide; Humans; Hypoglycemic Agents; Infant, Newborn; Insulin; Insulin Secretion; KATP Channels; Mutation; Nateglinide; Phenylalanine; Stimulation, Chemical; Sulfonylurea Compounds | 2009 |
Advances in oral therapy for type 2 diabetes.
Topics: Acarbose; Administration, Oral; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Metformin; Nateglinide; Phenylalanine; Piperidines; Randomized Controlled Trials as Topic; Thiazolidinediones; United States; Weight Gain | 2000 |
[Intestinal absorption and secretion mechanism of carboxylate drugs].
Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Agents, Phytogenic; Benzimidazoles; Benzoates; Camptothecin; Coumaric Acids; Cyclohexanes; Drug Interactions; Flavonoids; Food-Drug Interactions; Functional Food; Humans; Hypoglycemic Agents; Intestinal Absorption; Irinotecan; Monocarboxylic Acid Transporters; Nateglinide; Phenols; Phenylalanine; Polyphenols; Telmisartan | 2009 |
SLCO1B1 polymorphism and oral antidiabetic drugs.
Topics: Administration, Oral; Alleles; Carbamates; Cyclohexanes; Genotype; Haplotypes; Humans; Hypoglycemic Agents; Liver-Specific Organic Anion Transporter 1; Nateglinide; Organic Anion Transporters; Phenylalanine; Pioglitazone; Piperidines; Polymorphism, Genetic; Rosiglitazone; Thiazolidinediones | 2010 |
Diabetes prevention: can insulin secretagogues do the job?
Topics: Benzamides; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Disease Progression; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Nateglinide; Phenylalanine; Preventive Health Services; Sulfonylurea Compounds; Treatment Outcome | 2011 |
[Sulfonylureas and glinides].
Topics: Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Nateglinide; Phenylalanine; Sulfonylurea Compounds | 2011 |
Quo vadis nateglinide? Ten-year perspective.
Topics: Animals; Blood Glucose; Clinical Trials, Phase II as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Nateglinide; Phenylalanine; Randomized Controlled Trials as Topic | 2011 |
Variations in tissue selectivity amongst insulin secretagogues: a systematic review.
Topics: Animals; ATP-Binding Cassette Transporters; Carbamates; Cardiovascular Diseases; Cricetinae; Cyclohexanes; Diabetes Mellitus, Type 2; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Ischemic Preconditioning, Myocardial; Isoindoles; Mice; Muscle, Smooth, Vascular; Myocytes, Cardiac; Nateglinide; Phenylalanine; Piperidines; Potassium Channels, Inwardly Rectifying; Rats; Receptors, Drug; Risk Factors; Sulfonylurea Compounds; Sulfonylurea Receptors; Tolbutamide | 2012 |
Pharmacogenomics of glinides.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inactivation, Metabolic; Insulin; Insulin Secretion; Insulin-Secreting Cells; Isoindoles; KATP Channels; Nateglinide; Pharmacogenetics; Phenylalanine; Piperidines | 2015 |
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
Topics: Carbamates; Clinical Trials as Topic; Coronary Artery Disease; Cyclohexanes; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Metformin; Nateglinide; Phenylalanine; Piperidines; Sodium-Glucose Transport Proteins; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2015 |
Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Topics: Adult; Benzamides; Blood Glucose; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Fasting; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Middle Aged; Nateglinide; Phenylalanine; Randomized Controlled Trials as Topic; Sulfonylurea Compounds | 2016 |
Development of pharmacogenomic algorithm to optimize nateglinide dose for the treatment of type 2 diabetes mellitus.
Topics: Algorithms; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cyclohexanes; Cytochrome P-450 CYP2C9; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver-Specific Organic Anion Transporter 1; Nateglinide; Pharmacogenetics; Phenylalanine | 2022 |
102 trial(s) available for phenylalanine and nateglinide
| Article | Year |
|---|---|
Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
Topics: Administration, Oral; Biological Availability; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Intestinal Absorption; Molecular Structure; Nateglinide; Phenylalanine; Piperidines; Reference Values; Stereoisomerism | 1996 |
Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Eating; Fasting; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nateglinide; Phenylalanine; Time Factors | 2000 |
Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Kinetics; Male; Middle Aged; Nateglinide; Phenylalanine; Placebos; Proinsulin | 2000 |
Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Eating; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Nateglinide; Phenylalanine; Placebos; Safety | 2000 |
Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.
Topics: Adult; Aged; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Eating; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period | 2000 |
Mealtime glucose regulation by nateglinide in type-2 diabetes mellitus.
Topics: Blood Glucose; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nateglinide; Phenylalanine; Placebos | 2000 |
Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.
Topics: Aged; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Eating; Ethnicity; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Prospective Studies; United States | 2000 |
Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Body Weight; Carbamates; Cross-Over Studies; Cyclohexanes; Female; Food; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Kinetics; Male; Middle Aged; Nateglinide; Phenylalanine; Piperidines; Placebos; Time Factors | 2001 |
Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue.
Topics: Adult; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glucose; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Male; Middle Aged; Nateglinide; Obesity; Phenylalanine; Postprandial Period | 2000 |
Pharmacokinetics and metabolism of nateglinide in humans.
Topics: Administration, Oral; Adult; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Cross-Over Studies; Cyclohexanes; Humans; Hypoglycemic Agents; Injections, Intravenous; Intestinal Absorption; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Nateglinide; Phenylalanine; Radiopharmaceuticals | 2001 |
Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.
Topics: Aged; Area Under Curve; Blood Glucose; C-Peptide; Cyclohexanes; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Nateglinide; Phenylalanine; Placebos; Postprandial Period; Proinsulin; Single-Blind Method; Time Factors | 2001 |
Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).
Topics: Blood Glucose; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period | 2001 |
The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects.
Topics: Administration, Oral; Adult; Analysis of Variance; Biological Availability; Blood Glucose; Cross-Over Studies; Cyclohexanes; Dietary Fats; Fasting; Food-Drug Interactions; Humans; Hypoglycemic Agents; Insulin; Male; Nateglinide; Phenylalanine | 1999 |
Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects.
Topics: Area Under Curve; C-Peptide; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dietary Fats; Dietary Proteins; Double-Blind Method; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Time Factors | 2001 |
Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus.
Topics: Aged; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Tolerance Test; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Nateglinide; Phenylalanine; Reproducibility of Results; Sodium Chloride; Time Factors | 2001 |
Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients.
Topics: Aged; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Placebos; Racial Groups; Safety; Triglycerides | 2002 |
Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes.
Topics: Adult; Aged; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia.
Topics: Adult; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin; Insulin Secretion; Male; Nateglinide; Phenylalanine; Racial Groups; Treatment Outcome | 2002 |
A 3-way crossover study to evaluate the pharmacokinetic interaction between nateglinide and diclofenac in healthy volunteers.
Topics: Adult; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Cross-Over Studies; Cyclohexanes; Diclofenac; Drug Interactions; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Reference Values; Time Factors | 2002 |
Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Cyclohexanes; Double-Blind Method; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Prediabetic State | 2002 |
No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers.
Topics: Analysis of Variance; Anticoagulants; Area Under Curve; Cross-Over Studies; Cyclohexanes; Drug Administration Schedule; Drug Interactions; Humans; Hypoglycemic Agents; Male; Nateglinide; Phenylalanine; Prothrombin Time; Time Factors; Warfarin | 2002 |
Rapid and simple method for the analysis of nateglinide in human plasma using HPLC analysis with UV detection.
Topics: Anticonvulsants; Calibration; Carbamazepine; Chromatography, High Pressure Liquid; Cyclohexanes; Humans; Hypoglycemic Agents; Indicators and Reagents; Nateglinide; Phenylalanine; Quality Control; Reference Standards; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2003 |
Pharmacokinetics of nateglinide in renally impaired diabetic patients.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Case-Control Studies; Cyclohexanes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Half-Life; Humans; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Metabolic Clearance Rate; Middle Aged; Nateglinide; Phenylalanine; Renal Dialysis | 2003 |
The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects: rapid insulin stimulation by nateglinide in IGT subjects.
Topics: Area Under Curve; Blood Glucose; Cyclohexanes; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Prediabetic State | 2002 |
Efficacy and safety of nateglinide in the treatment of type II diabetes mellitus.
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Prospective Studies; Treatment Outcome | 2002 |
Evaluation of the effects of nateglinide on postprandial glycemia in patients with type 2 diabetes mellitus: a multicenter, multinational, non-randomized, non-controlled Latin American study.
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Latin America; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Treatment Outcome | 2003 |
Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Eating; Fasting; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Nateglinide; Phenylalanine; Placebos; Rosiglitazone; Safety; Single-Blind Method; Thiazolidinediones; Time Factors | 2003 |
Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
Topics: Area Under Curve; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Piperidines; Postprandial Period; Safety | 2003 |
Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide.
Topics: Adult; Area Under Curve; Blood Glucose; Cross-Over Studies; Cyclohexanes; Double-Blind Method; Female; Fluconazole; Humans; Male; Nateglinide; Phenylalanine; Statistics, Nonparametric | 2003 |
The effect of nateglinide taken with food on gastric emptying rates in healthy subjects.
Topics: Adult; Area Under Curve; Blood Glucose; Cross-Over Studies; Cyclohexanes; Double-Blind Method; Food-Drug Interactions; Gastric Emptying; Half-Life; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nateglinide; Phenylalanine; Time Factors | 2003 |
Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Cyclohexanes; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Renal Insufficiency; Time Factors | 2003 |
Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Family Practice; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Product Surveillance, Postmarketing | 2003 |
Effects of nateglinide on the secretion of glycated insulin and glucose tolerance in type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Glycosylation; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Male; Middle Aged; Nateglinide; Phenylalanine; Single-Blind Method | 2003 |
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects.
Topics: Adult; Antibiotics, Antitubercular; Area Under Curve; Blood Glucose; Cross-Over Studies; Cyclohexanes; Drug Interactions; Half-Life; Humans; Hypoglycemic Agents; Male; Nateglinide; Phenylalanine; Rifampin | 2003 |
Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Cyclohexanes; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Female; Glipizide; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period | 2003 |
The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol.
Topics: Acenocoumarol; Adult; Anticoagulants; Area Under Curve; Cross-Over Studies; Cyclohexanes; Double-Blind Method; Drug Interactions; Drug Tolerance; Female; Humans; Hypoglycemic Agents; Male; Nateglinide; Phenylalanine; Prothrombin Time; Safety | 2004 |
A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period | 2004 |
Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Prospective Studies; Statistics, Nonparametric | 2004 |
Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.
Topics: Adult; Alleles; Aryl Hydrocarbon Hydroxylases; Blood Glucose; Cyclohexanes; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Female; Genotype; Glucagon; Humans; Hypoglycemic Agents; Insulin; Male; Metabolic Clearance Rate; Nateglinide; Phenylalanine; Polymorphism, Genetic; Prospective Studies | 2004 |
Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.
Topics: Biomarkers; Body Mass Index; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Diet, Diabetic; Exercise; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Piperidines; Time Factors | 2004 |
Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects.
Topics: Adolescent; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cyclohexanes; Cytochrome P-450 CYP2C9; Enzyme Inhibitors; Female; Half-Life; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Sulfinpyrazone | 2004 |
Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.
Topics: Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Placebos; Treatment Outcome; United States | 2004 |
Nateglinide alone or with metformin safely improves glycaemia to target in patients up to an age of 84.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Prospective Studies; Regression Analysis | 2004 |
A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in Type 2 diabetic patients.
Topics: Administration, Oral; Blood Glucose; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium; Female; Forearm; Glucose; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nateglinide; Phenylalanine; Regional Blood Flow | 2004 |
Efficacy and safety of once daily gliclazide (20 mg/day) compared with nateglinide.
Topics: Adult; Cross-Over Studies; Cyclohexanes; Deoxyglucose; Diabetes Mellitus, Type 2; Gliclazide; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Malondialdehyde; Nateglinide; Phenylalanine; Prospective Studies; Serum Albumin; Thiobarbituric Acid Reactive Substances | 2004 |
Hypoglycemic potential of nateglinide versus glyburide in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Clamp Technique; Glyburide; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nateglinide; Phenylalanine | 2004 |
Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus--a randomized study using positron emission tomography.
Topics: Aged; Blood Glucose; Blood Pressure; Coronary Circulation; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipids; Male; Microcirculation; Middle Aged; Nateglinide; Phenylalanine; Positron-Emission Tomography; Treatment Outcome | 2005 |
Effects of nateglinide on the elevation of postprandial remnant-like particle triglyceride levels in Japanese patients with type 2 diabetes assessment by meal tolerance test.
Topics: Blood Glucose; Cholesterol; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Japan; Lipoproteins; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Triglycerides | 2004 |
[Comparison of efficacy between nateglinide and repaglinide in treating type 2 diabetes: a randomized controlled double-blind clinical trial].
Topics: Adult; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Nateglinide; Phenylalanine; Piperidines | 2005 |
Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide.
Topics: Aged; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Male; Middle Aged; Models, Biological; Nateglinide; Phenylalanine; Placebos; Severity of Illness Index | 2005 |
Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.
Topics: Adult; Aged; Blood Coagulation; Cardiovascular Diseases; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Fibrinolysis; Humans; Hypoglycemic Agents; Lipids; Male; Metabolism; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Treatment Outcome | 2005 |
Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.
Topics: Administration, Oral; Adult; Antifungal Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Blood Glucose; Cross-Over Studies; Cyclohexanes; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Gemfibrozil; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Itraconazole; Male; Nateglinide; Phenylalanine | 2005 |
PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin.
Topics: Body Mass Index; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Placebos | 2005 |
Beneficial effects of nateglinide on insulin resistance in type 2 diabetes.
Topics: Blood Glucose; Body Mass Index; Cyclohexanes; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period | 2006 |
Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Exercise Test; Female; Glucagon; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period | 2006 |
Efficacy and adverse effects of nateglinide in early type 2 diabetes. Comparison with voglibose in a cross-over study.
Topics: Aged; alpha-Glucosidases; Appetite; Body Weight; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Gastrointestinal Tract; Glycated Hemoglobin; Humans; Hypoglycemia; Inositol; Lipids; Liver Function Tests; Male; Middle Aged; Nateglinide; Phenylalanine; Treatment Outcome | 2006 |
Postprandial interstitial insulin concentrations in type 2 diabetes relatives.
Topics: Adipose Tissue; Adult; Anthropometry; Biological Transport; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Lipolysis; Male; Microdialysis; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Regional Blood Flow | 2006 |
Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Treatment Outcome | 2006 |
Nateglinide with glibenclamide examination using the respiratory quotient (RQ).
Topics: Aged; Blood Glucose; Body Weight; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Lipids; Male; Middle Aged; Nateglinide; Phenylalanine; Weight Gain | 2006 |
Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Blood Glucose; Blood Glucose Self-Monitoring; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Time Factors | 2007 |
Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes.
Topics: Acarbose; Arginine; Blood Glucose; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Nateglinide; Phenylalanine; Prospective Studies | 2007 |
Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results.
Topics: Aged; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Safety; Time Factors | 2007 |
Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial.
Topics: Adult; Age of Onset; Aged; Area Under Curve; Asian People; Blood Glucose; Carbamates; China; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Middle Aged; Nateglinide; Phenylalanine; Piperidines | 2007 |
Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control.
Topics: Aged; Blood Glucose; Carotid Arteries; Coronary Artery Disease; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Tunica Intima; Tunica Media | 2007 |
Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naïve elderly patients with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Treatment Outcome | 2008 |
Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial.
Topics: Adult; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Plasminogen Activator Inhibitor 1; Tissue Plasminogen Activator | 2007 |
Effect of combination therapy of a rapid-acting insulin secretagogue (glinide) with premixed insulin in type 2 diabetes mellitus.
Topics: Aged; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Isoindoles; Japan; Male; Middle Aged; Multicenter Studies as Topic; Nateglinide; Phenylalanine; Treatment Outcome | 2007 |
Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
Topics: Analysis of Variance; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Blood Glucose; Carbamates; Chromatography, Liquid; Cyclohexanes; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Dose-Response Relationship, Drug; Genotype; Half-Life; Humans; Hypoglycemic Agents; Liver-Specific Organic Anion Transporter 1; Metabolic Clearance Rate; Molecular Structure; Nateglinide; Organic Anion Transporters; Pharmacogenetics; Phenylalanine; Piperidines; Polymorphism, Single Nucleotide; Tablets; Tandem Mass Spectrometry | 2008 |
Improvement of glycaemic control by nateglinide decreases systolic blood pressure in drug-naive patients with type 2 diabetes.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Blood Pressure; Cholesterol; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Triglycerides | 2008 |
[Clinical evaluation of efficacy and safety of nateglinide in the treatment of type 2 diabetes].
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Treatment Outcome | 2008 |
Effects of acute and chronic attenuation of postprandial hyperglycemia on postglucose-load endothelial function in insulin resistant individuals: is stimulation of first phase insulin secretion beneficial for the endothelial function?
Topics: Blood Glucose; Case-Control Studies; Cyclohexanes; Endothelium; Female; Glucose; Humans; Hyperglycemia; Insulin; Insulin Resistance; Insulin Secretion; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Risk Factors; Vasodilation | 2008 |
Nateglinide may increase high-molecular weight adiponectin in type 2 diabetic patients with hypoadiponectinemia.
Topics: Adiponectin; Aged; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Molecular Weight; Nateglinide; Phenylalanine | 2008 |
Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
Topics: Administration, Oral; Adult; Area Under Curve; Blood Glucose; Carbamates; Cyclohexanes; Female; Haplotypes; Humans; Hypoglycemic Agents; Liver-Specific Organic Anion Transporter 1; Male; Nateglinide; Organic Anion Transporters; Phenylalanine; Piperidines; Time Factors | 2008 |
Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cyclohexanes; Diabetic Angiopathies; Disease Progression; Double-Blind Method; Glucose Intolerance; Humans; Hypoglycemic Agents; Life Style; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Research Design; Tetrazoles; Valine; Valsartan | 2008 |
Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
Topics: Blood Glucose; Body Mass Index; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Hemodynamics; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine | 2009 |
Nateglinide versus repaglinide for type 2 diabetes mellitus in China.
Topics: Carbamates; China; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Piperidines | 2009 |
Nateglinide combination therapy with basal insulin and metformin in patients with Type 2 diabetes.
Topics: Adult; Aged; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Young Adult | 2009 |
[A comparison of efficacy and tolerance of nateglinide and acarbose monotherapy in type 2 diabetes mellitus].
Topics: Acarbose; Adult; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Humans; Insulin Resistance; Male; Middle Aged; Nateglinide; Phenylalanine | 2009 |
Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.
Topics: Adamantane; Cyclohexanes; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Inhibitory Polypeptide; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Nateglinide; Nitriles; Phenylalanine; Pyrrolidines; Vildagliptin | 2009 |
Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Patient Selection; Phenylalanine; Prediabetic State; Research Design; Risk Assessment; Risk Factors; Tetrazoles; Valine; Valsartan | 2010 |
Effect of nateglinide on the incidence of diabetes and cardiovascular events.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Body Weight; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Nateglinide; Phenylalanine; Proportional Hazards Models; Risk Factors; Tetrazoles; Treatment Failure; Valine; Valsartan | 2010 |
Effect of valsartan on the incidence of diabetes and cardiovascular events.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Phenylalanine; Proportional Hazards Models; Risk Factors; Tetrazoles; Valine; Valsartan | 2010 |
Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study.
Topics: Acarbose; Aged; Blood Glucose; Brachial Artery; Cyclohexanes; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Food; Humans; Hypoglycemic Agents; Insulin; Laser-Doppler Flowmetry; Male; Middle Aged; Nateglinide; Phenylalanine; Vasodilation | 2010 |
[NAVIGATOR: A trial of prevention of cardiovascular complications and type 2 diabetes with valsartan and/or nateglinide].
Topics: Angiotensin II Type 1 Receptor Blockers; Belgium; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Additive hypoglycaemic effect of nateglinide and exogenous glucagon-like peptide-1 in type 2 diabetes.
Topics: Aged; Blood Glucose; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Male; Nateglinide; Phenylalanine; Postprandial Period; Treatment Outcome | 2011 |
Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Hyperglycemia; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period | 2011 |
Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes.
Topics: Acarbose; Adult; Aged; Aged, 80 and over; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Treatment Outcome | 2011 |
Efficacy and safety of mitiglinide versus nateglinide in newly diagnose patients with type 2 diabetes mellitus: a randomized double blind trial.
Topics: Blood Glucose; Body Mass Index; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Isoindoles; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Treatment Outcome; Waist-Hip Ratio | 2012 |
Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients.
Topics: Aged; Coronary Artery Disease; Cyclohexanes; Diabetes Complications; Diabetes Mellitus; Female; Glycemic Index; Humans; Hypoglycemic Agents; Inositol; Male; Middle Aged; Nateglinide; Phenylalanine | 2012 |
Relative fasting bioavailability of two formulations of nateglinide 60 mg in healthy male Chinese volunteers: an open-label, randomized-sequence, single-dose, two-way crossover study.
Topics: Adult; Analysis of Variance; Area Under Curve; Asian People; Biological Availability; China; Chromatography, Liquid; Cross-Over Studies; Cyclohexanes; Humans; Hypoglycemic Agents; Male; Nateglinide; Phenylalanine; Tandem Mass Spectrometry; Therapeutic Equivalency; Young Adult | 2012 |
Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers.
Topics: Administration, Oral; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asian People; Biomarkers; Blood Glucose; China; Cyclohexanes; Cytochrome P-450 CYP2C9; Genotype; Half-Life; Humans; Hypoglycemic Agents; Liver-Specific Organic Anion Transporter 1; Male; Metabolic Clearance Rate; Nateglinide; Organic Anion Transporters; Pharmacogenetics; Phenotype; Phenylalanine; Polymorphism, Single Nucleotide; Prospective Studies | 2013 |
Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study.
Topics: Adiposity; Aged; Albuminuria; Biomarkers; Blood Glucose; Creatinine; Cyclohexanes; Double-Blind Method; Female; Glucose Metabolism Disorders; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Incidence; Linear Models; Male; Middle Aged; Multivariate Analysis; Nateglinide; Nonlinear Dynamics; Obesity, Abdominal; Phenylalanine; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Waist Circumference | 2013 |
Effects of changes in potassium with valsartan use on diabetes risk: Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
Topics: Antihypertensive Agents; Biomarkers; Cyclohexanes; Diabetes Mellitus; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Potassium; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2013 |
Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
Topics: Adiponectin; Blood Glucose; Body Mass Index; C-Reactive Protein; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Hepatocytes; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Lipolysis; Male; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2013 |
Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes.
Topics: Acarbose; Adolescent; Adult; Antihypertensive Agents; Area Under Curve; Blood Glucose; China; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Glycemic Index; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Prospective Studies; Treatment Outcome | 2013 |
Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
Topics: Aged; Atrial Fibrillation; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Proportional Hazards Models; Risk Assessment; Risk Factors; Tetrazoles; Valine; Valsartan | 2013 |
Comparison of effects of α-Glucosidase inhibitors and glinide drugs on endothelial dysfunction in diabetic patients with coronary artery disease.
Topics: 1-Deoxynojirimycin; Aged; Aged, 80 and over; Coronary Artery Disease; Cyclohexanes; Diabetic Angiopathies; Dyslipidemias; Endothelium, Vascular; Enzyme Inhibitors; Female; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Middle Aged; Nateglinide; Phenylalanine | 2014 |
Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.
Topics: Adamantane; Adolescent; Adult; Blood Glucose; Cyclohexanes; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Healthy Volunteers; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Liraglutide; Male; Maximum Tolerated Dose; Metformin; Middle Aged; Nateglinide; Nitriles; Phenylalanine; Prognosis; Pyrrolidines; Somatostatin; Vildagliptin; Young Adult | 2014 |
Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Confidence Intervals; Cyclohexanes; Female; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Prevalence; Proportional Hazards Models; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Valine; Valsartan; Venous Thromboembolism | 2015 |
Differential therapeutic effects of nateglinide and acarbose on fasting and postprandial lipid profiles: a randomized trial.
Topics: Acarbose; Adult; China; Cholesterol, HDL; Cholesterol, LDL; Cyclohexanes; Diabetes Mellitus, Type 2; Dyslipidemias; Fasting; Female; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Prospective Studies; Time Factors; Triglycerides | 2015 |
A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
Topics: 1-Deoxynojirimycin; Adult; Benzhydryl Compounds; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Interactions; Glucose; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Inositol; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones; Urine; Young Adult | 2016 |
Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study.
Topics: Body Weight; Cyclohexanes; Double-Blind Method; Glucose Intolerance; Humans; Hypoglycemic Agents; Life Style; Motor Activity; Nateglinide; Phenylalanine; Prospective Studies; Valsartan | 2015 |
203 other study(ies) available for phenylalanine and nateglinide
| Article | Year |
|---|---|
Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals.
Topics: Animals; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Experimental; Dogs; Glucose Tolerance Test; Glyburide; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Mice; Mice, Mutant Strains; Nateglinide; Phenylalanine; Rats; Rats, Inbred Strains; Tolbutamide | 1991 |
N-(cyclohexylcarbonyl)-D-phenylalanines and related compounds. A new class of oral hypoglycemic agents. 2.
Topics: Administration, Oral; Animals; Blood Glucose; Chemical Phenomena; Chemistry; Cyclohexanes; Dogs; Hypoglycemic Agents; Magnetic Resonance Spectroscopy; Male; Mice; Molecular Conformation; Nateglinide; Phenylalanine | 1989 |
Insulinotropic action of meglitinide analogs: concentration-response relationship and nutrient dependency.
Topics: Animals; Benzamides; Carbamates; Cyclohexanes; Female; Glucose; Hypoglycemic Agents; In Vitro Techniques; Indoles; Insulin; Insulin Secretion; Islets of Langerhans; Isoindoles; Molecular Structure; Nateglinide; Phenylalanine; Piperidines; Rats; Structure-Activity Relationship; Succinates | 1994 |
Effects of D-phenylalanine-derivative hypoglycemic agent A-4166 on pancreatic alpha- and beta-cells: comparative study with glibenclamide.
Topics: Analysis of Variance; Animals; Cyclohexanes; Diazoxide; Drug Interactions; Glucagon; Glyburide; Hypoglycemic Agents; In Vitro Techniques; Insulin; Insulin Secretion; Islets of Langerhans; Male; Nateglinide; Perfusion; Phenylalanine; Rats; Rats, Wistar | 1995 |
A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic beta-cells.
Topics: Adenosine Triphosphate; Animals; Calcium Channels; Cyclohexanes; Dose-Response Relationship, Drug; Electrophysiology; Hydrogen-Ion Concentration; Hypoglycemic Agents; Islets of Langerhans; Male; Membrane Potentials; Nateglinide; Phenylalanine; Potassium Channel Blockers; Potassium Channels; Rats; Rats, Wistar; Tolbutamide | 1995 |
A novel D-phenylalanine-derivative hypoglycemic agent A-4166 increases cytosolic free Ca2+ in rat pancreatic beta-cells by stimulating Ca2+ influx.
Topics: Animals; Calcium; Cyclohexanes; Cytosol; Diazoxide; Dose-Response Relationship, Drug; Glucose; Hypoglycemic Agents; Islets of Langerhans; Nateglinide; Nitrendipine; Phenylalanine; Potassium Channels; Rats; Rats, Wistar; Sulfonylurea Compounds | 1994 |
Effects of N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166) on insulin and glucagon secretion in isolated perfused rat pancreas.
Topics: Animals; Cyclohexanes; Glucagon; Glucose; Hypoglycemic Agents; In Vitro Techniques; Insulin; Insulin Secretion; Nateglinide; Pancreas; Perfusion; Phenylalanine; Radioimmunoassay; Rats | 1994 |
Ionophoretic properties of the non-sulfonylurea hypoglycemic agents A-4166 and KAD-1229.
Topics: Calcium; Calcium Radioisotopes; Cyclohexanes; Hypoglycemic Agents; Indoles; Ionophores; Isoindoles; Kinetics; Membranes, Artificial; Nateglinide; Phenylalanine; Sodium Chloride | 1995 |
Stimulating activity of A-4166 on insulin release in in situ hamster pancreatic perfusion.
Topics: Animals; Blood Glucose; Cricetinae; Cyclohexanes; Diazoxide; Drug Interactions; Glyburide; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Mesocricetus; Nateglinide; Pancreas; Perfusion; Phenylalanine; Vasodilator Agents | 1995 |
Somatostatin and insulin secretion due to common mechanisms by a new hypoglycemic agent, A-4166, in perfused rat pancreas.
Topics: Adenosine Triphosphate; Animals; Calcium; Calcium Channels; Cyclohexanes; Glucagon; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Nateglinide; Pancreas; Perfusion; Phenylalanine; Potassium Channels; Rats; Rats, Wistar; Somatostatin; Time Factors | 1996 |
Conformational analysis of non-sulfonylurea hypoglycemic agents of the meglitinide family.
Topics: Benzamides; Carbamates; Cyclohexanes; Drug Design; Glyburide; Hypoglycemic Agents; Indoles; Isoindoles; Molecular Conformation; Nateglinide; Phenylalanine; Piperidines; Stereoisomerism; Structure-Activity Relationship; Sulfonylurea Compounds | 1995 |
Studies on the N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanin e (A-4166)receptor in HIT T-15 cells. Displacement of [3H]glibenclamide.
Topics: Animals; Binding Sites; Cricetinae; Cyclohexanes; Dose-Response Relationship, Drug; Glyburide; Hypoglycemic Agents; Mice; Nateglinide; Phenylalanine; Radioligand Assay | 1996 |
Effect of food on the bioavailability of SDZ DJN 608, an oral hypoglycemic agent, from a tablet and a liquid-filled capsule in the dog.
Topics: Administration, Oral; Amino Acid Transport Systems; Animals; Biological Availability; Caco-2 Cells; Capsules; Carrier Proteins; Dogs; Epithelium; Food; Humans; Hypoglycemic Agents; Intestinal Absorption; Male; Phenylalanine; Tablets | 1996 |
Determination of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine in human plasma by solid-phase extraction and column-switching high-performance liquid chromatography with ultraviolet detection.
Topics: Chromatography, High Pressure Liquid; Cyclohexanes; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Reproducibility of Results; Sensitivity and Specificity | 1996 |
Insulinotropic action of meglitinide analogues: modulation by an activator of ATP-sensitive K+ channels and high extracellular K+ concentrations.
Topics: Animals; Benzamides; Carbamates; Cyclohexanes; Female; Hypoglycemic Agents; Indoles; Insulin; Insulin Secretion; Islets of Langerhans; Isoindoles; Nateglinide; Phenylalanine; Piperidines; Potassium; Rats | 1995 |
Effects of the methyl esters of pyruvate, succinate and glutamate on the secretory response to meglitinide analogues in rat pancreatic islets.
Topics: Animals; Carbamates; Cells, Cultured; Cyclohexanes; Glucose; Glutamates; Hypoglycemic Agents; Indoles; Insulin; Insulin Secretion; Islets of Langerhans; Isoindoles; Nateglinide; Phenylalanine; Piperidines; Pyruvates; Rats; Succinates | 1996 |
Structure determination of metabolites isolated from urine and bile after administration of AY4166, a novel D-phenylalanine-derivative hypoglycemic agent.
Topics: Animals; Bile; Cyclohexanes; Dogs; Glucuronidase; Humans; Hypoglycemic Agents; Magnetic Resonance Spectroscopy; Models, Molecular; Nateglinide; Phenylalanine | 1996 |
Fate of 3H- and 14C-labelled A-4166 in pancreatic islets.
Topics: Animals; Autoradiography; Carbon Radioisotopes; Cells, Cultured; Cyclohexanes; Female; Hypoglycemic Agents; Islets of Langerhans; Nateglinide; Phenylalanine; Rats; Rats, Wistar; Tritium | 1996 |
The ability of a new hypoglycaemic agent, A-4166, compared to sulphonylureas, to increase cytosolic Ca2+ in pancreatic beta-cells under metabolic inhibition.
Topics: Animals; Calcium; Cyclohexanes; Cytosol; Electron Transport; Enzyme Inhibitors; Gliclazide; Glucokinase; Glucose; Hypoglycemic Agents; Islets of Langerhans; Mitochondria; Nateglinide; Oxidative Phosphorylation; Phenylalanine; Rats; Rats, Wistar; Sulfonylurea Compounds; Tolbutamide | 1997 |
Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166).
Topics: Animals; Binding, Competitive; Blood Glucose; Calcium; Cell Line; Cyclohexanes; Diazoxide; Diuretics; Dogs; Glyburide; Hypoglycemic Agents; In Vitro Techniques; Insulin; Insulin Secretion; Islets of Langerhans; Male; Nateglinide; Phenylalanine; Rats; Rats, Wistar; Sodium Chloride Symporter Inhibitors; Stimulation, Chemical | 1997 |
Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide.
Topics: Animals; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Experimental; Enzyme Inhibitors; Glucose; Glyburide; Hypoglycemic Agents; Inositol; Insulin; Male; Nateglinide; Phenylalanine; Postprandial Period; Rats; Rats, Wistar; Sucrose | 1997 |
Determination of N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine and its metabolites in human plasma and urine by column-switching high-performance liquid chromatography with ultraviolet detection.
Topics: Chromatography, High Pressure Liquid; Cyclohexanes; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Reference Standards; Spectrophotometry, Ultraviolet | 1997 |
Dynamics of the cationic and secretory responses to A-4166 in perifused pancreatic islets.
Topics: Animals; Benzamides; Calcium; Cyclohexanes; Female; Glucose; Hypoglycemic Agents; Insulin; Insulin Secretion; Nateglinide; Pancreas; Phenylalanine; Rats; Rats, Wistar; Rubidium; Time Factors | 1997 |
Insulin secretion from isolated rat islets induced by the novel hypoglycemic agent A-4166, a derivative of D-phenylalanine.
Topics: Animals; ATP-Binding Cassette Transporters; Biological Availability; Calcium; Cell Line; Cyclohexanes; Diazoxide; Epinephrine; Glucose; Glyburide; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Male; Nateglinide; Phenylalanine; Potassium Channels; Potassium Channels, Inwardly Rectifying; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Drug; Rubidium; Somatostatin; Stereoisomerism; Sulfonylurea Receptors; Tolbutamide | 1998 |
Ay-4166 increases the sensitivity of insulin secretion to glucose in isolated perfused rat pancreas.
Topics: Animals; Cyclohexanes; Dose-Response Relationship, Drug; Glucose; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Nateglinide; Pancreas; Perfusion; Phenylalanine; Rats; Rats, Wistar | 1998 |
Interaction of N-benzoyl-D-phenylalanine and related compounds with the sulphonylurea receptor of beta-cells.
Topics: Adenosine Triphosphate; Animals; ATP-Binding Cassette Transporters; Calcium; Carbutamide; Cell Line, Transformed; Cricetinae; Cyclohexanes; Glyburide; Guanosine Diphosphate; Islets of Langerhans; Male; Mice; Nateglinide; Phenylalanine; Potassium Channels; Potassium Channels, Inwardly Rectifying; Receptors, Drug; Sulfonylurea Receptors; Tritium | 1998 |
Stimulation of insulin and somatostatin release by two meglitinide analogs.
Topics: Animals; Benzamides; Blood Glucose; Carbamates; Cyclohexanes; Female; Glucagon; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Nateglinide; Perfusion; Phenylalanine; Piperidines; Rats; Rats, Wistar; Somatostatin | 1997 |
Effect of N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine on nutrient catabolism in rat pancreatic islets.
Topics: Animals; Benzamides; Cyclohexanes; Female; Glucose; Hypoglycemic Agents; Islets of Langerhans; Leucine; Nateglinide; Oxidation-Reduction; Phenylalanine; Rats; Rats, Wistar | 1998 |
The effect of the new oral hypoglycemic agent A-4166 on glucose turnover in the high fat diet-induced and/or in the hereditary insulin resistance of rats.
Topics: Animals; Body Weight; Cyclohexanes; Deoxyglucose; Dietary Fats; Glucose; Glucose Clamp Technique; Hypoglycemic Agents; Insulin Resistance; Male; Nateglinide; Phenylalanine; Phosphorylation; Rats; Rats, Wistar | 1998 |
Tissue selectivity of antidiabetic agent nateglinide: study on cardiovascular and beta-cell K(ATP) channels.
Topics: Animals; Aorta, Thoracic; Carbamates; Cardiovascular System; Coronary Vessels; Cyclohexanes; Glyburide; Heart; Hypoglycemic Agents; Islets of Langerhans; Male; Muscle, Smooth, Vascular; Nateglinide; Phenylalanine; Piperidines; Potassium Channels; Potassium Channels, Inwardly Rectifying; Rats; Rats, Sprague-Dawley; Swine | 1999 |
Stimulation of insulin release in hereditarily diabetic rats by mixed molecules formed of nateglinide and a succinic acid ester.
Topics: Animals; Cyclohexanes; Diabetes Mellitus; Hypoglycemic Agents; Insulin; Molecular Structure; Nateglinide; Phenylalanine; Rats; Rats, Inbred Strains; Succinates; Time Factors | 2000 |
Selectivity of prandial glucose regulators: nateglinide, but not repaglinide, accelerates exocytosis in rat pancreatic A-cells.
Topics: Animals; ATP-Binding Cassette Transporters; Calcium; Carbamates; Cyclohexanes; Eating; Electrophysiology; Exocytosis; Glucagon; Glucose; Hypoglycemic Agents; In Vitro Techniques; Islets of Langerhans; KATP Channels; Kinetics; Male; Nateglinide; Patch-Clamp Techniques; Phenylalanine; Piperidines; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Inwardly Rectifying; Rats; Rats, Inbred Lew; Stimulation, Chemical | 1999 |
Long-term effects of glibenclamide and nateglinide upon pancreatic islet function in normal and diabetic rats.
Topics: Animals; Blood Glucose; Cyclohexanes; Diabetes Mellitus; Female; Glyburide; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Nateglinide; Phenylalanine; Rats; Rats, Wistar | 1999 |
Effects of a new hypoglycemic agent A-4166 on glucose metabolism in rat adipocytes and muscle tissues.
Topics: Adipocytes; Animals; Biological Transport; Cyclohexanes; Deoxyglucose; Dietary Fats; Glucose; Glucose Transporter Type 4; Glycolysis; Hypoglycemic Agents; In Vitro Techniques; Insulin; Lipids; Male; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Nateglinide; Phenylalanine; Rats; Rats, Wistar | 1999 |
Inhibitory effect of novel oral hypoglycemic agent nateglinide (AY4166) on peptide transporters PEPT1 and PEPT2.
Topics: Administration, Oral; Alanine; Animals; Caco-2 Cells; Carrier Proteins; Cyclohexanes; Dipeptides; Humans; Hypoglycemic Agents; Kinetics; Nateglinide; Peptide Transporter 1; Phenylalanine; Rats; Symporters; Threonine | 2000 |
Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
Topics: Animals; ATP-Binding Cassette Transporters; Binding, Competitive; Carbamates; Cell Membrane; Cell Separation; Cells, Cultured; Cyclohexanes; Glucose; Glyburide; Glycosyltransferases; Humans; Hypoglycemia; Hypoglycemic Agents; In Vitro Techniques; Insulin; Islets of Langerhans; KATP Channels; Kinetics; Male; Membrane Proteins; Nateglinide; Patch-Clamp Techniques; Phenylalanine; Piperidines; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Inwardly Rectifying; Rats; Rats, Sprague-Dawley; Repressor Proteins; Saccharomyces cerevisiae Proteins; Sulfonylurea Compounds | 2000 |
Senaglinide. A 4166, AY 4166, Fastic, SDZ DJN 608, Starlix, Starsis, YM 026, Nateglinide.
Topics: Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine | 1999 |
Inhibitory effect of anti-diabetic agents on rat organic anion transporter rOAT1.
Topics: Animals; Anion Transport Proteins; Binding, Competitive; Carbon Radioisotopes; Carrier Proteins; Chlorpropamide; Cyclohexanes; Dose-Response Relationship, Drug; Female; Glyburide; Hypoglycemic Agents; Kinetics; Nateglinide; Oocytes; p-Aminohippuric Acid; Phenylalanine; Rats; RNA, Complementary; Sulfonylurea Compounds; Tolbutamide; Xenopus | 2000 |
Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis.
Topics: Adult; Aged; Cyclohexanes; Female; Humans; Hypoglycemic Agents; Liver Cirrhosis; Male; Middle Aged; Nateglinide; Phenylalanine | 2000 |
Effects of new hypoglycemic agent A-4166 on lipolysis and lipogenesis in rat adipocytes.
Topics: Adipocytes; Animals; Blood Glucose; Cyclohexanes; Fatty Acids, Nonesterified; Hypertension; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Lipolysis; Male; Nateglinide; Norepinephrine; Phenylalanine; Rats; Rats, Wistar | 2000 |
[Fasting blood glucose has little value. Postprandial glucose indicates risk].
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Postprandial Period; Risk Factors | 2001 |
FDA approves nateglinide for treatment of type 2 diabetes.
Topics: Cyclohexanes; Diabetes Mellitus, Type 2; Drug Approval; Hypoglycemic Agents; Nateglinide; Phenylalanine; United States; United States Food and Drug Administration | 2001 |
[New glucose regulator. More comfort for the type 2 diabetic patient].
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine | 2001 |
Nateglinide for type 2 diabetes.
Topics: Administration, Oral; Cyclohexanes; Diabetes Mellitus, Type 2; Dizziness; Humans; Metformin; Nateglinide; Phenylalanine | 2001 |
Differential effects of short and long duration insulinotropic agents on meal-related glucose excursions.
Topics: Animals; Blood Glucose; Carbamates; Cyclohexanes; Food; Glipizide; Glucagon; Insulin; Insulin Secretion; Male; Nateglinide; Phenylalanine; Piperidines; Rats; Rats, Sprague-Dawley | 2001 |
Early insulin release effectively improves glucose tolerance: studies in two rodent models of type 2 diabetes mellitus.
Topics: Animals; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Dietary Fats; Gastric Emptying; Glipizide; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Kinetics; Male; Nateglinide; Phenylalanine; Rats; Rats, Sprague-Dawley; Rats, Zucker | 2001 |
[Therapy of type 2 diabetes. Effective control of postprandial glucose surges].
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Administration Schedule; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Postprandial Period | 2001 |
Immediate-Type allergy against human insulin associated with marked eosinophilia in type 2 diabetic patient.
Topics: Aged; Aged, 80 and over; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Hypersensitivity; Eosinophilia; Erythema; Humans; Hypersensitivity, Immediate; Hypoglycemic Agents; Immunoglobulin E; Insulin; Male; Nateglinide; Phenylalanine; Seasons; Skin Tests | 2001 |
Effect of insulinotropic agent nateglinide on Kv and Ca(2+) channels in pancreatic beta-cell.
Topics: Animals; Calcium Channels; Carbamates; Cyclohexanes; Dose-Response Relationship, Drug; Electric Stimulation; Glyburide; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Male; Membrane Potentials; Nateglinide; Patch-Clamp Techniques; Phenylalanine; Piperidines; Potassium Channels; Rats; Rats, Sprague-Dawley | 2001 |
[Type 2 diabetes. Regulating insulin according to need].
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Nateglinide; Phenylalanine; Thiazoles; Thiazolidinediones | 2001 |
The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide.
Topics: Animals; ATP-Binding Cassette Transporters; Cell Line; COS Cells; Cyclohexanes; Glyburide; Hypoglycemic Agents; Indoles; Insulin; Isoindoles; Nateglinide; Patch-Clamp Techniques; Phenylalanine; Potassium Channels; Potassium Channels, Inwardly Rectifying; Receptors, Drug; Sulfonylurea Compounds; Sulfonylurea Receptors; Tolbutamide; Transfection | 2001 |
Improvement of glucose tolerance by nateglinide occurs through enhancement of early phase insulin secretion.
Topics: Adult; Aged; Blood Glucose; Cyclohexanes; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Time Factors | 2002 |
Post-load hyperglycaemia-an inappropriate therapeutic target.
Topics: Blood Glucose; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Nateglinide; Patient Selection; Phenylalanine; Postprandial Period; Practice Guidelines as Topic; Predictive Value of Tests | 2002 |
Type 2 diabetes management.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Piperidines | 2002 |
Comparison of insulinotrophic actions of nateglinide with glibenclamide dissociated from absorption in conscious dogs.
Topics: Absorption; Animals; ATP-Binding Cassette Transporters; Blood Glucose; Cell Membrane; Cyclohexanes; Dogs; Female; Glucose Clamp Technique; Glyburide; Hypoglycemic Agents; Insulin; Intestinal Absorption; Kinetics; Male; Nateglinide; Phenylalanine; Potassium Channels; Potassium Channels, Inwardly Rectifying; Receptors, Drug; Sulfonylurea Receptors | 2002 |
Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action.
Topics: Adenosine Triphosphate; Animals; Carbamates; Cyclohexanes; Dose-Response Relationship, Drug; Glucose; Glyburide; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Kinetics; Male; Membrane Potentials; Nateglinide; Phenylalanine; Piperidines; Potassium Channel Blockers; Potassium Channels; Rats; Rats, Sprague-Dawley; Sulfonylurea Compounds; Time Factors | 2002 |
Nateglinide, but not repaglinide, stimulates growth hormone release in rat pituitary cells by inhibition of K channels and stimulation of cyclic AMP-dependent exocytosis.
Topics: Animals; Calcium; Carbamates; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclohexanes; Delayed Rectifier Potassium Channels; Exocytosis; Growth Hormone; Growth Hormone-Releasing Hormone; Hypoglycemic Agents; Male; Membrane Potentials; Nateglinide; Patch-Clamp Techniques; Phenylalanine; Piperidines; Pituitary Gland; Potassium; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Rats; Rats, Sprague-Dawley | 2002 |
[Dangerous postprandial glucose peaks. Risk for heart and blood vessels].
Topics: Cyclohexanes; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Metformin; Nateglinide; Phenylalanine; Postprandial Period | 2002 |
[Islands cells are not activated quickly enough. Risk of obstruction of blood vessels].
Topics: Arteriosclerosis; Blood Glucose; Cyclohexanes; Diabetic Angiopathies; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Islets of Langerhans; Metformin; Nateglinide; Phenylalanine; Postprandial Period; Risk | 2002 |
Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1.
Topics: ATP-Binding Cassette Transporters; Binding, Competitive; Carbamates; Cell Line; Cyclohexanes; Drug Interactions; Electrophysiology; Humans; Islets of Langerhans; Nateglinide; Phenylalanine; Piperidines; Potassium Channels; Potassium Channels, Inwardly Rectifying; Receptors, Drug; Sulfonylurea Receptors; Tolbutamide | 2002 |
Transport and uptake of nateglinide in Caco-2 cells and its inhibitory effect on human monocarboxylate transporter MCT1.
Topics: Administration, Oral; Analysis of Variance; Animals; Biological Transport; Caco-2 Cells; Cyclohexanes; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Monocarboxylic Acid Transporters; Nateglinide; Oocytes; Phenylalanine; Protons; Symporters; Temperature; Time Factors; Xenopus laevis | 2002 |
New drugs 2002, part 1.
Topics: Amides; Aminosalicylic Acids; Anti-Ulcer Agents; Antipsychotic Agents; Bimatoprost; Cloprostenol; Cyclohexanes; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Galantamine; Glaucoma; Gonadotropin-Releasing Hormone; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Lipids; Mesalamine; Nateglinide; Nootropic Agents; Phenylalanine; Phenylhydrazines; Piperazines; Thiazoles; Travoprost | 2002 |
Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide.
Topics: Animals; Carbamates; Cyclohexanes; Glucose; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Kinetics; Male; Nateglinide; Phenylalanine; Piperidines; Rats; Rats, Sprague-Dawley; Sulfonylurea Compounds | 2001 |
Effectiveness of nateglinide on in vitro insulin secretion from rat pancreatic islets desensitized to sulfonylureas.
Topics: Animals; Carbamates; Cyclohexanes; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Male; Nateglinide; Phenylalanine; Piperidines; Rats; Rats, Sprague-Dawley; Sulfonylurea Compounds | 2001 |
Decreased blood glucose excursion by nateglinide ameliorated neuropathic changes in Goto-Kakizaki rats, an animal model of non-obese type 2 diabetes.
Topics: Animals; Area Under Curve; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Glyburide; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Nateglinide; Phenylalanine; Postprandial Period; Rats; Rats, Inbred Strains; Rats, Wistar; Sciatic Nerve; Time Factors | 2002 |
Nateglinide suppresses postprandial hypertriglyceridemia in Zucker fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamide.
Topics: Animals; Blood Glucose; Cyclohexanes; Glyburide; Hypertriglyceridemia; Inositol; Male; Nateglinide; Phenylalanine; Postprandial Period; Rats; Rats, Wistar; Rats, Zucker; Species Specificity | 2002 |
[Glinides and glitazones in diabetes treatment. Are they really effective?].
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cohort Studies; Costs and Cost Analysis; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Female; Glycated Hemoglobin; Health Care Costs; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Economic; Nateglinide; Phenylalanine; Postprandial Period | 2002 |
Pharmacodynamics, insulinotropic action and hypoglycemic effect of nateglinide and glibenclamide in normal and diabetic rats.
Topics: Animals; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Experimental; Female; Glyburide; Hypoglycemic Agents; Insulin; Insulin Secretion; Liver; Nateglinide; Pancreas; Phenylalanine; Rats; Rats, Wistar; Reference Values; Tissue Distribution | 2003 |
[Interrelations of the pancreas exocrine and endocrine functions in chronic alcohol pancreatitis].
Topics: Adult; Amylases; Cyclohexanes; Humans; Hypoglycemic Agents; Islets of Langerhans; Lipase; Middle Aged; Nateglinide; Pancreas; Pancreatitis, Alcoholic; Phenylalanine; Trypsin | 2002 |
[Detection of crystal polymorphs of nateglinide by DSC].
Topics: Calorimetry, Differential Scanning; Crystallization; Cyclohexanes; Nateglinide; Phenylalanine; Quality Control | 2002 |
A new crystal form of nateglinide.
Topics: Crystallization; Crystallography, X-Ray; Cyclohexanes; Hypoglycemic Agents; Nateglinide; Phenylalanine; Powder Diffraction; Spectroscopy, Fourier Transform Infrared | 2001 |
Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure.
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Kidney Failure, Chronic; Middle Aged; Nateglinide; Phenylalanine | 2003 |
Nateglinide, a D-phenylalanine derivative lacking either a sulfonylurea or benzamido moiety, specifically inhibits pancreatic beta-cell-type K(ATP) channels.
Topics: Adenosine Diphosphate; ATP-Binding Cassette Transporters; Cells, Cultured; Cyclohexanes; Electrophysiology; Humans; Islets of Langerhans; KATP Channels; Nateglinide; Phenylalanine; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Inwardly Rectifying; Sulfonylurea Compounds | 2003 |
Pharmacologic restoration of the early insulin response in pre-diabetic monkeys controls mealtime glucose excursions without peripheral hyperinsulinaemia.
Topics: Animals; Blood Glucose; Carbamates; Cyclohexanes; Fatty Acids, Nonesterified; Food; Glucagon; Hypoglycemic Agents; Insulin; Insulin Secretion; Kinetics; Macaca fascicularis; Male; Nateglinide; Phenylalanine; Piperidines | 2003 |
[Differences between oral antidiabetics].
Topics: Administration, Oral; Carbamates; Cyclohexanes; Diabetes Mellitus; Glipizide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Nateglinide; Phenylalanine; Piperidines; Sulfonylurea Compounds | 2003 |
Repaglinide at a cellular level.
Topics: Animals; Carbamates; Cyclohexanes; Electrophysiology; Exocytosis; Hypoglycemic Agents; Islets of Langerhans; Membrane Potentials; Nateglinide; Phenylalanine; Piperidines; Postprandial Period; Potassium Channels; Rats | 2002 |
Should diabetic patients treated long-term with sulfonylureas be switched to nateglinide?
Topics: Adult; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Nateglinide; Phenylalanine; Sulfonylurea Compounds; Time | 2003 |
[Fasting hyperglycemia and postprandial glucose peaks. Diabetes therapy mustact on 2 sides].
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Postprandial Period | 2003 |
Improvement of insulin resistance by a new insulin secretagogue, nateglinide--analysis based on the homeostasis model.
Topics: Aged; Blood Glucose; Body Mass Index; Cyclohexanes; Glycated Hemoglobin; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Kinetics; Middle Aged; Models, Biological; Nateglinide; Phenylalanine; Regression Analysis | 2003 |
Contrasting effects of nateglinide and rosiglitazone on insulin secretion and phospholipase C activation.
Topics: Androstadienes; Animals; Chromans; Cyclohexanes; Enzyme Activation; Glucose; Hypoglycemic Agents; Indicators and Reagents; Inositol Phosphates; Insulin; Insulin Secretion; Islets of Langerhans; Male; Nateglinide; Perfusion; Phenylalanine; Rats; Rats, Sprague-Dawley; Rosiglitazone; Signal Transduction; Thiazolidinediones; Troglitazone; Type C Phospholipases; Wortmannin | 2003 |
Glimepiride and serum adiponectin level in type 2 diabetic subjects: response to Nagasaka et al.
Topics: Adiponectin; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Nateglinide; Phenylalanine; Piperidines; Proteins; Sulfonylurea Compounds | 2003 |
Comparison of repaglinide and nateglinide in combination with metformin: response to Raskin et al.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Piperidines | 2003 |
Comparison of voglibose and nateglinide for their acute effects on insulin secretion and free fatty acid levels in OLETF rat portal blood after sucrose loading.
Topics: Animals; Area Under Curve; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Disease Models, Animal; Enzyme Inhibitors; Fatty Acids, Nonesterified; Hypoglycemic Agents; Inositol; Insulin; Insulin Secretion; Male; Nateglinide; Phenylalanine; Portal Vein; Postprandial Period; Rats; Rats, Inbred OLETF; Secretory Rate; Sucrose | 2004 |
Novartis breached code after doctors say it "invented" a disease.
Topics: Advertising; Blood Glucose; Cyclohexanes; Diabetes Complications; Diabetes Mellitus; Disclosure; Drug Industry; Europe; Family Practice; Humans; Hyperglycemia; Hypoglycemic Agents; Meta-Analysis as Topic; Nateglinide; Phenylalanine; Prospective Studies; Risk; United Kingdom | 2002 |
[Achieving better control of blood sugar--understanding of oral hypoglycemic agents according to their characteristics in pharmacological action mechanism (discussion)].
Topics: Administration, Oral; Cardiovascular Diseases; Cyclohexanes; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Indoles; Inositol; Insulin; Insulin Resistance; Insulin Secretion; Isoindoles; Nateglinide; Phenylalanine; Risk Factors; Stimulation, Chemical; Sulfonylurea Compounds; Thiazolidinediones | 2004 |
Acute and long-term effects of nateglinide on insulin secretory pathways.
Topics: Animals; Cattle; Cyclohexanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Insulin; Insulin Secretion; Nateglinide; Phenylalanine; Rats; Time Factors | 2004 |
Restoration of early insulin secretion after a meal in type 2 diabetes: effects on lipid and glucose metabolism.
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period | 2004 |
H+-dependent transport mechanism of nateglinide in the brush-border membrane of the rat intestine.
Topics: Animals; Biological Transport; Ceftibuten; Cephalosporins; Cyclohexanes; Dose-Response Relationship, Drug; Hypoglycemic Agents; Intestine, Small; Microvilli; Nateglinide; Phenylalanine; Protons; Rats | 2005 |
Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes.
Topics: Carbamates; Cohort Studies; Computer Simulation; Cost of Illness; Cost-Benefit Analysis; Cyclohexanes; Decision Support Systems, Clinical; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Health Care Costs; Humans; Male; Metformin; Middle Aged; Models, Econometric; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Piperidines; Quality-Adjusted Life Years | 2004 |
[A compensated type 2 diabetic patient? Fasting blood glucose can be deceptive].
Topics: Blood Glucose; Clinical Trials as Topic; Cyclohexanes; Diabetes Mellitus, Type 2; Fasting; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Postprandial Period | 2004 |
Determination of nateglinide in animal plasma by micellar electrokinetic chromatography and on-line sweeping technique.
Topics: Animals; Buffers; Chromatography, Micellar Electrokinetic Capillary; Cyclohexanes; Hydrogen-Ion Concentration; Nateglinide; Phenylalanine; Rabbits; Reproducibility of Results; Sensitivity and Specificity; Specimen Handling | 2004 |
Study on the bioavailability of nateglinide-hydroxypropyl-beta-cyclodextrin complex capsule in rabbits by liquid chromatographic-tandem mass spectrometry.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; beta-Cyclodextrins; Biological Availability; Capsules; Chemistry, Pharmaceutical; Chromatography, Liquid; Cyclohexanes; Male; Mass Spectrometry; Nateglinide; Phenylalanine; Quality Control; Rabbits; Sensitivity and Specificity | 2004 |
Role of early insulin secretion in postglucose-loading hyperglycaemia and postfat-loading hyperlipidaemia: comparing nateglinide and glibenclamide for acute effects on insulin secretion in OLETF rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Dietary Fats; Gene Expression Regulation; Glyburide; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipoprotein Lipase; Male; Nateglinide; Phenylalanine; Postprandial Period; Rats; Rats, Inbred OLETF; Rats, Long-Evans; RNA, Messenger; Triglycerides | 2004 |
Sulfonylurea induced beta-cell apoptosis in cultured human islets.
Topics: Adult; Aged; Apoptosis; Calcium; Carbamates; Cells, Cultured; Cyclohexanes; Dose-Response Relationship, Drug; Glyburide; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Middle Aged; Nateglinide; Phenylalanine; Piperidines | 2005 |
Treating type 2 diabetes. When diet and exercise aren't enough, a broad range of medications can help control our blood sugar.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Administration Schedule; Eating; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Piperidines | 2004 |
Alterations of insulin secretion following long-term manipulation of ATP-sensitive potassium channels by diazoxide and nateglinide.
Topics: Adenosine Triphosphate; Cell Line; Cyclohexanes; Diazoxide; Drug Administration Schedule; Humans; Insulin; Insulin Secretion; Nateglinide; Phenylalanine; Potassium Channel Blockers; Potassium Channels | 2005 |
Hypoglycemia following a nateglinide overdose in a suicide attempt.
Topics: Adult; Blood Glucose; Cyclohexanes; Drug Overdose; Female; Glucose; Humans; Hypoglycemic Agents; Infusions, Intravenous; Nateglinide; Phenylalanine; Suicide, Attempted | 2005 |
Weight loss-associated changes in acute effects of nateglinide on insulin secretion after glucose loading: results of glucose loading on 2 consecutive days.
Topics: Adipose Tissue; Administration, Oral; Blood Glucose; C-Peptide; Cyclohexanes; Fatty Acids, Nonesterified; Female; Glucose Tolerance Test; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Liver; Male; Middle Aged; Muscle, Skeletal; Nateglinide; Obesity; Phenylalanine; Weight Loss | 2005 |
Intestinal uptake of nateglinide by an intestinal fluorescein transporter.
Topics: Absorption; Biological Transport; Caco-2 Cells; Carrier Proteins; Cyclohexanes; Fluorescein; Humans; Hydrogen-Ion Concentration; Intestinal Mucosa; Membrane Transport Proteins; Metabolic Clearance Rate; Nateglinide; Phenylalanine | 2005 |
Food-drug interaction between ferulic acid and nateglinide involving the fluorescein/H+ cotransport system.
Topics: Caco-2 Cells; Coumaric Acids; Cyclohexanes; Drug Interactions; Fluorescein; Food; Humans; Hypoglycemic Agents; Intestinal Mucosa; Monocarboxylic Acid Transporters; Nateglinide; Phenylalanine | 2005 |
Intestinal perforation caused by stagnated press-through packages.
Topics: Aged; Cyclohexanes; Diabetes Mellitus; Drug Packaging; Female; Foreign Bodies; Humans; Hypoglycemic Agents; Intestinal Perforation; Jejunum; Nateglinide; Phenylalanine; Tomography, X-Ray Computed | 2005 |
Indication for nateglinide in type 2 diabetes mellitus.
Topics: Age Factors; Aged; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Obesity; Phenylalanine | 2005 |
Nateglinide, a non-sulfonylurea rapid insulin secretagogue, increases pancreatic islet blood flow in rats.
Topics: 3-O-Methylglucose; Administration, Oral; Anesthesia; Animals; Blood Glucose; Blood Pressure; Consciousness; Cyclohexanes; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Gastrointestinal Tract; Glucose; Hypoglycemic Agents; Injections, Intravenous; Insulin; Insulin Secretion; Islets of Langerhans; Male; Nateglinide; Nitric Oxide Synthase; omega-N-Methylarginine; Phenylalanine; Rats; Rats, Inbred OLETF; Rats, Sprague-Dawley; Regional Blood Flow; Time Factors; Tolbutamide | 2005 |
Substrate specificity of the nateglinide/H(+) cotransport system for phenolic acids.
Topics: Biological Transport; Caco-2 Cells; Caffeic Acids; Coumaric Acids; Cyclohexanes; Flavonoids; Humans; Hypoglycemic Agents; Nateglinide; Phenols; Phenylalanine; Polyphenols; Propionates; Protons; Symporters | 2005 |
Nateglinide uptake by a ceftibuten transporter in the rat kidney brush-border membrane.
Topics: Animals; Ceftibuten; Cephalosporins; Cyclohexanes; Ion Transport; Kidney; Male; Microvilli; Nateglinide; Peptide Transporter 1; Phenylalanine; Protons; Rats; Rats, Wistar; Symporters | 2005 |
Rapid and efficient chiral separation of nateglinide and its L-enantiomer on monolithic molecularly imprinted polymers.
Topics: Acrylic Resins; Chromatography, High Pressure Liquid; Cyclohexanes; Microscopy, Electron, Scanning; Nateglinide; Phenylalanine; Stereoisomerism; Thermodynamics | 2005 |
Effect of rosiglitazone and nateglinide on serum glucose and lipid profile alone or in combination with the biguanide metformin in diabetic rats.
Topics: Animals; Blood Glucose; Blood Proteins; Cholesterol; Cyclohexanes; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Hypoglycemic Agents; Lipid Metabolism; Lipids; Male; Metformin; Nateglinide; Phenylalanine; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Triglycerides | 2006 |
Purification by p-aminobenzoic acid (PABA)-affinity chromatography and the functional reconstitution of the nateglinide/H+ cotransport system in the rat intestinal brush-border membrane.
Topics: 4-Aminobenzoic Acid; Animals; Benzoic Acid; Biological Transport; Ceftibuten; Cell Membrane; Cephalosporins; Chromatography, Affinity; Chromatography, High Pressure Liquid; Cyclohexanes; Dioxins; Dose-Response Relationship, Drug; Durapatite; Electrophoresis, Polyacrylamide Gel; Fluorescein; Hypoglycemic Agents; Intestinal Mucosa; Intestine, Small; Liposomes; Male; Microvilli; Nateglinide; Phenylalanine; Proteolipids; Protons; Rats; Rats, Wistar; Salicylic Acid; Ultraviolet Rays | 2006 |
Determination of the nateglinide polymorphism structure and the drug effect.
Topics: Animals; Blood Glucose; Crystallization; Cyclohexanes; Female; Hyperglycemia; Hypoglycemic Agents; Male; Mice; Mice, Inbred ICR; Nateglinide; Phenylalanine; X-Ray Diffraction | 2005 |
Elimination of metformin-croscarmellose sodium interaction by competition.
Topics: Arginine; Binding, Competitive; Carboxymethylcellulose Sodium; Cyclohexanes; Drug Combinations; Excipients; Hypoglycemic Agents; Metformin; Models, Chemical; Nateglinide; Phenylalanine; Tablets; Technology, Pharmaceutical | 2006 |
[Synthesis and insulinotropic activity of 2-benzylidenesuccinic acid derivatives].
Topics: Animals; Benzylidene Compounds; Blood Glucose; Carbamates; Cyclohexanes; Hypoglycemic Agents; Indoles; Isoindoles; Mice; Molecular Structure; Nateglinide; Phenylalanine; Piperidines; Structure-Activity Relationship; Succinates | 2005 |
Effect of decrease in both postprandial blood glucose (PBG) and fasting blood glucose (FBG) levels in normal beagle dogs with nateglinide enteric coated granules and immediate release tablets.
Topics: Administration, Oral; Animals; Blood Glucose; Cyclohexanes; Delayed-Action Preparations; Diabetes Mellitus; Dogs; Fasting; Hydrogen-Ion Concentration; Hypoglycemic Agents; Nateglinide; Phenylalanine; Solubility; Tablets, Enteric-Coated | 2006 |
Favorable effects of early insulin secretion by nateglinide on postprandial hyperlipidemia in patients with type 2 diabetes.
Topics: Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Secretion; Nateglinide; Phenylalanine; Postprandial Period; Triglycerides | 2006 |
Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Glyburide; Indoles; Insulin; Insulin Secretion; Isoindoles; Lipoprotein Lipase; Male; Nateglinide; Phenylalanine; Portal Vein; Postprandial Period; Prediabetic State; Rats; Rats, Inbred OLETF; RNA, Messenger; Sulfonylurea Compounds; Triglycerides | 2006 |
Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide.
Topics: Adult; Cyclohexanes; Diabetes Mellitus; Humans; Hypoglycemic Agents; Liver-Specific Organic Anion Transporter 1; Male; Nateglinide; Organic Anion Transporters; Phenylalanine; Polymorphism, Single Nucleotide | 2006 |
Insulin and nateglinide reduce monocyte adhesion to endothelial cells in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation.
Topics: Animals; Aorta; Blood Glucose; Body Weight; Cell Adhesion; Cyclohexanes; Endothelial Cells; Gene Expression Regulation; Insulin; Intercellular Adhesion Molecule-1; Male; Monocytes; Nateglinide; Phenylalanine; Rats; RNA, Messenger; Vascular Cell Adhesion Molecule-1 | 2006 |
Actions of glucagon-like peptide-1 on KATP channel-dependent and -independent effects of glucose, sulphonylureas and nateglinide.
Topics: Cell Line; Colforsin; Cyclic AMP-Dependent Protein Kinases; Cyclohexanes; Dose-Response Relationship, Drug; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Nateglinide; Phenylalanine; Potassium Channels; Protein Kinase C; Stimulation, Chemical; Sulfonylurea Compounds; Tetradecanoylphorbol Acetate | 2006 |
Glibenclamide attenuates the antiarrhythmic effect of endotoxin with a mechanism not involving K(ATP) channels.
Topics: Action Potentials; Adenosine Triphosphate; Animals; Arrhythmias, Cardiac; Blood Pressure; Carbamates; Cyclohexanes; Disease Models, Animal; Drug Interactions; Endotoxemia; Glyburide; Heart Atria; Heart Conduction System; Lipopolysaccharides; Male; Myocardial Ischemia; Nateglinide; Phenylalanine; Piperidines; Potassium Channel Blockers; Potassium Channels; Rats; Rats, Sprague-Dawley; Tachycardia, Ventricular; Tetraethylammonium; Time Factors; Ventricular Fibrillation; Ventricular Premature Complexes | 2007 |
[Evaluation of first phase insulin secretion by a nateglinide-intravenous glucose insulin release test in newly diagnosed type 2 diabetics].
Topics: Adult; Case-Control Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Evaluation Studies as Topic; Female; Glucose; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Middle Aged; Nateglinide; Phenylalanine | 2006 |
Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach.
Topics: ATP-Binding Cassette Transporters; Computer Simulation; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Gene Expression Regulation; Glipizide; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Pioglitazone; Potassium Channels; Potassium Channels, Inwardly Rectifying; PPAR gamma; Protein Binding; Receptors, Drug; Sulfonylurea Compounds; Sulfonylurea Receptors; Thiazolidinediones | 2007 |
Effects of the combination of a dipeptidyl peptidase IV inhibitor and an insulin secretagogue on glucose and insulin levels in mice and rats.
Topics: Animals; Blood Glucose; Cyclohexanes; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glyburide; Imidazoles; Insulin; Male; Mice; Mice, Inbred C57BL; Nateglinide; Phenylalanine; Protease Inhibitors; Pyridazines; Rats; Rats, Wistar; Tosyl Compounds | 2007 |
Key role of insulin resistance in vascular injury among hemodialysis patients.
Topics: Aged; Blood Pressure; Carnitine; Cyclohexanes; Diabetic Nephropathies; Female; Homeostasis; Humans; Hypoglycemic Agents; Insulin Resistance; Lipoprotein Lipase; Lipoproteins, LDL; Male; Middle Aged; Nateglinide; Phenylalanine; Regression Analysis; Renal Dialysis; Vascular Diseases | 2007 |
Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic beta-cell death in the chronic phase.
Topics: Animals; Apoptosis; Calcium Channels; Cyclohexanes; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; KATP Channels; Mice; Nateglinide; Phenylalanine; Sulfonylurea Compounds; Time Factors | 2007 |
Nateglinide quantification in rabbit plasma by HPLC: optimization and application to pharmacokinetic study.
Topics: Administration, Oral; Animals; Area Under Curve; Buffers; Calibration; Chromatography, High Pressure Liquid; Cold Temperature; Cyclohexanes; Drug Stability; Freezing; Half-Life; Hydrogen-Ion Concentration; Hypoglycemic Agents; Metabolic Clearance Rate; Molecular Structure; Nateglinide; Phenylalanine; Rabbits; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Time Factors | 2007 |
Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum.
Topics: Animals; Calcium; Cell Line; Cyclohexanes; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Hypoglycemic Agents; Indoles; Insulin; Insulin Secretion; Insulin-Secreting Cells; Isoindoles; Mice; Nateglinide; Phenylalanine; Ryanodine Receptor Calcium Release Channel; Sulfonylurea Compounds | 2007 |
Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A + B-site ligands.
Topics: Amino Acid Substitution; Animals; ATP-Binding Cassette Transporters; Binding Sites; Binding, Competitive; Carbamates; Cell Line; Cyclohexanes; Dose-Response Relationship, Drug; Glyburide; Hypoglycemic Agents; KATP Channels; Ligands; Mice; Molecular Structure; Nateglinide; Phenylalanine; Piperidines; Potassium Channels; Potassium Channels, Inwardly Rectifying; Protein Binding; Radioligand Assay; Rats; Receptors, Drug; Sulfonylurea Compounds; Sulfonylurea Receptors; Transfection | 2007 |
A validated stability indicating LC method for Nateglinide.
Topics: Chromatography, High Pressure Liquid; Cyclohexanes; Drug Contamination; Drug Stability; Hot Temperature; Hydrogen-Ion Concentration; Hypoglycemic Agents; Nateglinide; Oxidation-Reduction; Phenylalanine; Reproducibility of Results; Ultraviolet Rays | 2007 |
Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
Topics: Animals; Blood Glucose; Cell Line; Cyclohexanes; Diabetes Mellitus; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Mice; Mice, Obese; Nateglinide; Peptide Fragments; Phenylalanine | 2007 |
Development and validation of a stereoselective HPLC method for the determination of the in vitro transport of nateglinide enantiomers in rat intestine.
Topics: Animals; Calibration; Chromatography; Chromatography, High Pressure Liquid; Cyclohexanes; Hydrogen-Ion Concentration; Hypoglycemic Agents; Intestinal Mucosa; Male; Nateglinide; Phenylalanine; Phosphates; Potassium Compounds; Rats; Rats, Wistar; Reproducibility of Results; Stereoisomerism | 2007 |
Determination of nateglinide in human plasma by high-performance liquid chromatography with pre-column derivatization using a coumarin-type fluorescent reagent.
Topics: Acetamides; Chromatography, High Pressure Liquid; Coumarins; Cyclohexanes; Fluorescent Dyes; Humans; Hypoglycemic Agents; Indicators and Reagents; Nateglinide; Phenylalanine; Reproducibility of Results | 2007 |
Safety of nateglinide as used in general practice in England: results of a prescription-event monitoring study.
Topics: Aged; Confidentiality; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Prescriptions; England; Family Practice; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Safety | 2007 |
Potential utility of combination therapy with nateglinide and telmisartan for metabolic derangements in Zucker Fatty rats.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Body Weight; Cyclohexanes; Drug Therapy, Combination; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Lipids; Male; Metabolic Diseases; Nateglinide; Phenylalanine; Rats; Rats, Zucker; Telmisartan | 2007 |
Octreotide therapy for nateglinide-induced hypoglycemia.
Topics: Aged; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Gastrointestinal Agents; Glucose; Humans; Hypoglycemia; Hypoglycemic Agents; Nateglinide; Octreotide; Phenylalanine; Treatment Outcome | 2007 |
Nateglinide prevents fatty liver through up-regulation of lipid oxidation pathway in Goto-Kakizaki rats on a high-fat diet.
Topics: Animals; Blood Glucose; Cyclohexanes; Dietary Fats; Disease Models, Animal; Fatty Acids, Nonesterified; Fatty Liver; Hypoglycemic Agents; Insulin; Male; Nateglinide; Phenylalanine; Rats; Rats, Inbred Strains; Rats, Wistar; Triglycerides | 2008 |
Prediction of the metabolic interaction of nateglinide with other drugs based on in vitro studies.
Topics: Aryl Hydrocarbon Hydroxylases; Biotransformation; Cyclohexanes; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Humans; Hypoglycemic Agents; In Vitro Techniques; Kinetics; Microsomes, Liver; Models, Biological; Nateglinide; Phenylalanine | 2007 |
Insulin exocytosis in Goto-Kakizaki rat beta-cells subjected to long-term glinide or sulfonylurea treatment.
Topics: Animals; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Experimental; Exocytosis; Glyburide; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Male; Nateglinide; Phenylalanine; Rats; Rats, Wistar; SNARE Proteins; Sulfonylurea Compounds; Time Factors | 2008 |
Postprandial hyperglycemia: are all sulfonylureas created equal?
Topics: Carbamates; Cyclohexanes; Glipizide; Humans; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Nateglinide; Phenylalanine; Piperidines; Postprandial Period; Sulfonylurea Compounds | 2008 |
Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of nateglinide, cilostazol and its active metabolite 3,4-dehydro-cilostazol in Wistar rat plasma and its application to pharmacokinetic
Topics: Animals; Chromatography, Liquid; Cilostazol; Cyclohexanes; Nateglinide; Phenylalanine; Rats; Rats, Wistar; Reference Standards; Reproducibility of Results; Tandem Mass Spectrometry; Tetrazoles | 2008 |
Differential effect of sulfonylureas on production of reactive oxygen species and apoptosis in cultured pancreatic beta-cell line, MIN6.
Topics: Animals; Apoptosis; Cell Line; Cyclohexanes; Fluoresceins; Gliclazide; Glyburide; Hypoglycemic Agents; In Situ Nick-End Labeling; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Microscopy, Fluorescence; NADPH Oxidases; Nateglinide; Phenylalanine; Protein Kinase C; Reactive Oxygen Species; Sulfonylurea Compounds | 2008 |
Studies in the development of nateglinide loaded calcium alginate and chitosan coated calcium alginate beads.
Topics: Alginates; Calcium; Calorimetry, Differential Scanning; Chitosan; Cyclohexanes; Drug Carriers; Drug Delivery Systems; Glucuronic Acid; Hexuronic Acids; Kinetics; Microspheres; Nateglinide; Particle Size; Phenylalanine; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2008 |
Change in long-spacing collagen in Descemet's membrane of diabetic Goto-Kakizaki rats and its suppression by antidiabetic agents.
Topics: Animals; Collagen; Cornea; Cyclohexanes; Descemet Membrane; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Glyburide; Hypoglycemic Agents; Immunohistochemistry; Male; Microscopy, Immunoelectron; Nateglinide; Phenylalanine; Rats; Rats, Inbred Strains; Rats, Wistar; Reference Values | 2008 |
Pharmacokinetics of nateglinide enantiomers and their metabolites in Goto-Kakizaki rats, a model for type 2 diabetes mellitus.
Topics: Animals; Cyclohexanes; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Male; Nateglinide; Phenylalanine; Rats; Rats, Wistar; Stereoisomerism | 2010 |
Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.
Topics: Administration, Oral; Adult; Adverse Drug Reaction Reporting Systems; Carbamates; Cohort Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Prescriptions; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Sex Factors; Thiazolidinediones | 2009 |
Thermodynamic relationships between nateglinide polymorphs.
Topics: Chemistry, Pharmaceutical; Chemistry, Physical; Crystallization; Crystallography, X-Ray; Cyclohexanes; Hot Temperature; Hypoglycemic Agents; Microscopy, Electron, Scanning; Models, Chemical; Molecular Structure; Nateglinide; Phenylalanine; Spectrophotometry; Spectrophotometry, Infrared; Spectroscopy, Fourier Transform Infrared; Technology, Pharmaceutical; Temperature; Thermodynamics | 2009 |
Panel discussion on achieving glycemic control.
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Sulfonylurea Compounds | 2001 |
Design of nateglinide controlled release tablet containing erosion matrix tablet and multiple administration study in normal beagle dogs.
Topics: Administration, Oral; Animals; Biological Availability; Blood Glucose; Cyclohexanes; Delayed-Action Preparations; Dogs; Drug Compounding; Hydrogen-Ion Concentration; Hypoglycemic Agents; Nateglinide; Phenylalanine; Tablets; Time Factors | 2009 |
Effect of glimepiride and nateglinide on serum insulin and glucose concentration in healthy cats.
Topics: Animals; Blood Glucose; Cat Diseases; Cats; Cyclohexanes; Diabetes Mellitus; Female; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Male; Nateglinide; Phenylalanine; Sulfonylurea Compounds | 2009 |
New solid modifications of nateglinide.
Topics: Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Crystallization; Crystallography, X-Ray; Cyclohexanes; Drug Stability; Drug Storage; Humidity; Hypoglycemic Agents; Nateglinide; Phenylalanine; Powder Diffraction; Spectroscopy, Fourier Transform Infrared; Technology, Pharmaceutical; Thermogravimetry; Transition Temperature; Water | 2010 |
Glinide, but not sulfonylurea, can evoke insulin exocytosis by repetitive stimulation: imaging analysis of insulin exocytosis by secretagogue-induced repetitive stimulations.
Topics: Animals; Calcium; Carbamates; Cell Fusion; Cells, Cultured; Cyclohexanes; Exocytosis; Glucose; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Microscopy, Fluorescence; Nateglinide; Phenylalanine; Piperidines; Sulfonylurea Compounds | 2009 |
Diabetes under control: Understanding oral antidiabetic agents.
Topics: Administration, Oral; Biguanides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Piperidines; Sulfonylurea Compounds | 2010 |
Navigating the choices for diabetes prevention.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose Intolerance; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Tetrazoles; Valine; Valsartan | 2010 |
Inhibition of human liver microsomal CYP by nateglinide.
Topics: Cyclohexanes; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Hypoglycemic Agents; Inhibitory Concentration 50; Liver; Microsomes; Nateglinide; Pharmaceutical Preparations; Phenylalanine; Risk | 2010 |
Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats.
Topics: Adamantane; Animals; Blood Glucose; Cyclohexanes; Drug Therapy, Combination; Fatty Acids; Forkhead Transcription Factors; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Liver; Male; Metabolic Diseases; Nateglinide; Nerve Tissue Proteins; Nitriles; Organ Size; Phenylalanine; Phosphorylation; Postprandial Period; Pyrrolidines; Rats; Rats, Zucker; Triglycerides; Vildagliptin | 2010 |
Effect of fluvastatin, lovastatin, nifedipine and verapamil on the systemic exposure of nateglinide in rabbits.
Topics: Animals; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Calcium Channel Blockers; Cyclohexanes; Cytochrome P-450 CYP2C9; Cytochrome P450 Family 2; Diabetes Mellitus, Type 2; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Indoles; Lovastatin; Male; Nateglinide; Nifedipine; Phenylalanine; Rabbits; Steroid 21-Hydroxylase; Verapamil | 2010 |
Nateglinide controlled release tablet containing compressionable enteric coated granules.
Topics: Administration, Oral; Animals; Blood Glucose; Cyclohexanes; Delayed-Action Preparations; Dogs; Hypoglycemic Agents; Male; Nateglinide; Phenylalanine; Solubility; Tablets, Enteric-Coated | 2010 |
Modeling of ATP-sensitive inward rectifier potassium channel 11 and inhibition mechanism of the natural ligand, ellagic acid, using molecular docking.
Topics: Binding Sites; Caco-2 Cells; Computational Biology; Computer-Aided Design; Cyclohexanes; Drug Design; Drug Discovery; Ellagic Acid; Humans; Hypoglycemic Agents; In Vitro Techniques; KATP Channels; Ligands; Models, Molecular; Nateglinide; Phenylalanine; Structural Homology, Protein; Sulfonylurea Compounds | 2010 |
Combination therapy with nateglinide and telmisartan ameliorates insulin resistance in zucker Fatty rats by suppressing advanced glycation end product receptor axis.
Topics: Animals; Benzimidazoles; Benzoates; Cyclohexanes; Disease Models, Animal; Down-Regulation; Drug Therapy, Combination; Glycation End Products, Advanced; Humans; Insulin Resistance; Liver; Male; Nateglinide; Phenylalanine; Rats; Rats, Zucker; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Telmisartan | 2011 |
Determination of the L-enantiomer of nateglinide in pharmaceutical formulations by micellar electrokinetic chromatography.
Topics: beta-Cyclodextrins; Buffers; Chromatography, Micellar Electrokinetic Capillary; Cyclohexanes; Hydrogen-Ion Concentration; Hypoglycemic Agents; Micelles; Nateglinide; Pharmaceutical Preparations; Phenylalanine; Reproducibility of Results; Sodium Dodecyl Sulfate; Stereoisomerism | 2010 |
Determination of the nateglinide polymorphic purity through DSC.
Topics: Calorimetry, Differential Scanning; Crystallization; Cyclohexanes; Drug Compounding; Drug Contamination; Hydrogen-Ion Concentration; Hypoglycemic Agents; Nateglinide; Phenylalanine; Transition Temperature | 2011 |
Nateglinide stimulates glucagon-like peptide-1 release by human intestinal L cells via a K(ATP) channel-independent mechanism.
Topics: Animals; Cell Line; Cyclohexanes; Glucagon-Like Peptide 1; Humans; Intestinal Mucosa; Intestines; Male; Nateglinide; Phenylalanine; Potassium Channels; Rats; Rats, Wistar | 2011 |
Hypersensitivity to repaglinide.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Hypersensitivity; Erythema; Exanthema; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Patch Tests; Phenylalanine; Piperidines | 2011 |
Compatibility studies of nateglinide with excipients in immediate release tablets.
Topics: Calorimetry, Differential Scanning; Chemical Phenomena; Cyclohexanes; Drug Compounding; Drug Incompatibility; Drug Stability; Excipients; Hardness; Hypoglycemic Agents; Kinetics; Mechanical Phenomena; Nateglinide; Phenylalanine; Solubility; Spectroscopy, Fourier Transform Infrared; Stearic Acids; Tablets; Temperature | 2011 |
Stereoselective binding of chiral anti-diabetic drug nateglinide to plasma proteins.
Topics: Blood Proteins; Cyclohexanes; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Protein Binding; Serum Albumin; Stereoisomerism | 2011 |
Comparison of the rapidity of onset of the therapeutic effect between nateglinide and mitiglinide by PK/PD analysis in rats.
Topics: Administration, Intravenous; Administration, Oral; Animals; ATP-Binding Cassette Transporters; Cyclohexanes; Hypoglycemic Agents; Isoindoles; Models, Biological; Nateglinide; Phenylalanine; Potassium Channels, Inwardly Rectifying; Rats; Rats, Sprague-Dawley; Receptors, Drug; Sulfonylurea Receptors; Time Factors | 2012 |
From evidence assessments to coverage decisions?: the case example of glinides in Germany.
Topics: Carbamates; Cost Control; Cost-Benefit Analysis; Costs and Cost Analysis; Cyclohexanes; Diabetes Mellitus; Eligibility Determination; Evidence-Based Medicine; Germany; Health Care Reform; Health Policy; Humans; Hypoglycemic Agents; Insurance Coverage; Nateglinide; National Health Programs; Phenylalanine; Piperidines; Prescription Drugs; Reimbursement Mechanisms; Technology Assessment, Biomedical | 2012 |
Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A.
Topics: ATP-Binding Cassette Transporters; Chlorpropamide; Cyclohexanes; Diabetes Mellitus, Type 2; Gene Expression Regulation; Gliclazide; Glyburide; Haplotypes; Homozygote; Humans; Isoindoles; Nateglinide; Patch-Clamp Techniques; Phenylalanine; Polymorphism, Single Nucleotide; Potassium Channels, Inwardly Rectifying; Receptors, Drug; Structure-Activity Relationship; Sulfonylurea Compounds; Sulfonylurea Receptors; Tolbutamide | 2012 |
Contribution of organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 to hepatic uptake of nateglinide, and the prediction of drug-drug interactions via these transporters.
Topics: Biological Transport; Cells, Cultured; Cyclohexanes; Drug Interactions; Hepatocytes; Humans; Hypoglycemic Agents; Liver-Specific Organic Anion Transporter 1; Models, Theoretical; Nateglinide; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Phenylalanine; Solute Carrier Organic Anion Transporter Family Member 1B3; Time Factors | 2012 |
Intensive glucose lowering in cardiovascular risk management - unsolved questions - .
Topics: Coronary Artery Disease; Cyclohexanes; Diabetes Mellitus; Female; Glycemic Index; Humans; Inositol; Male; Nateglinide; Phenylalanine | 2012 |
Estimating relative stability of polymorphs by generation of configurational free energy phase diagram.
Topics: Calorimetry, Differential Scanning; Carbamazepine; Cyclohexanes; Models, Theoretical; Nateglinide; Phenylalanine; Powder Diffraction; Solubility; Thermodynamics | 2012 |
Synthesis and characterization of carboxymethyl chitosan hydrogel: application as pH-sensitive delivery for nateglinide.
Topics: Chitosan; Cross-Linking Reagents; Cyclohexanes; Drug Carriers; Glutaral; Hydrogel, Polyethylene Glycol Dimethacrylate; Hydrogen-Ion Concentration; Hypoglycemic Agents; Nateglinide; Phenylalanine | 2012 |
Effect of piperine on antihyperglycemic activity and pharmacokinetic profile of nateglinide.
Topics: Alkaloids; Alloxan; Animals; Benzodioxoles; Cyclohexanes; Diabetes Mellitus, Experimental; Drug Interactions; Drug Synergism; Glucose Tolerance Test; Hypoglycemic Agents; Male; Nateglinide; Phenylalanine; Piperidines; Polyunsaturated Alkamides; Rats; Rats, Wistar | 2012 |
[Glinides].
Topics: Benzamides; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine | 2012 |
Synthesis and biological investigations of nitric oxide releasing nateglinide and meglitinide type II antidiabetic prodrugs: in-vivo antihyperglycemic activities and blood pressure lowering studies.
Topics: Benzamides; Blood Pressure; Cyclohexanes; Humans; Hypoglycemic Agents; Magnetic Resonance Spectroscopy; Nateglinide; Nitric Oxide; Phenylalanine; Prodrugs; Spectrometry, Mass, Electrospray Ionization | 2012 |
Evaluating insulin secretagogues in a humanized mouse model with functional human islets.
Topics: Animals; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glyburide; Humans; Incretins; Insulin; Insulin Secretion; Islets of Langerhans; Islets of Langerhans Transplantation; Male; Mice; Mice, Nude; Nateglinide; Peptides; Phenylalanine; Pyrazines; Sitagliptin Phosphate; Specific Pathogen-Free Organisms; Triazoles; Venoms | 2013 |
Lyophilized oral sustained release polymeric nanoparticles of nateglinide.
Topics: Administration, Oral; Animals; Cyclohexanes; Freeze Drying; Hypoglycemic Agents; Male; Microscopy, Electron, Scanning; Nanoparticles; Nateglinide; Phenylalanine; Polymers; Rats; Rats, Wistar; Spectroscopy, Fourier Transform Infrared | 2013 |
Nateglinide in combination with metformin in Chinese patients with type 2 diabetes mellitus: a post-marketing surveillance study.
Topics: Aged; Body Weight; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Product Surveillance, Postmarketing; Prospective Studies | 2013 |
I. Technological approaches to improve the dissolution behavior of nateglinide, a lipophilic insoluble drug: nanoparticles and co-mixing.
Topics: Administration, Oral; Chemistry, Pharmaceutical; Crystallization; Cyclohexanes; Excipients; Hydrogen-Ion Concentration; Hypoglycemic Agents; Kinetics; Nanoparticles; Nanotechnology; Nateglinide; Phenylalanine; Polymers; Solubility; Technology, Pharmaceutical | 2013 |
II. Technological approaches to improve the dissolution behavior of nateglinide, a lipophilic insoluble drug: co-milling.
Topics: Carboxymethylcellulose Sodium; Chemistry, Pharmaceutical; Cyclohexanes; Drug Carriers; Excipients; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hypoglycemic Agents; Kinetics; Mannitol; Nateglinide; Particle Size; Phenylalanine; Poloxamer; Povidone; Silicon Dioxide; Solubility; Starch; Technology, Pharmaceutical | 2013 |
Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
Topics: Aged; Antihypertensive Agents; Comorbidity; Controlled Clinical Trials as Topic; Cyclohexanes; Drug Therapy, Combination; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Predictive Value of Tests; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan | 2013 |
Characterization of monocarboxylate transporter 6: expression in human intestine and transport of the antidiabetic drug nateglinide.
Topics: Animals; Biological Transport; Caco-2 Cells; Cell Line, Tumor; Cyclohexanes; Female; Humans; Hydrogen-Ion Concentration; Hypoglycemic Agents; Intestinal Absorption; Intestine, Small; Membrane Potentials; Membrane Transport Proteins; Monocarboxylic Acid Transporters; Nateglinide; Oocytes; Phenylalanine; Rats; Xenopus laevis | 2013 |
Postprandial lipid profile in patients with type 2 diabetes.
Topics: Acarbose; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Humans; Hyperlipidemias; Hypoglycemic Agents; Nateglinide; Phenylalanine; Postprandial Period | 2014 |
Formulation and in vitro evaluation of nateglinide microspheres using HPMC and carbopol-940 polymers by ionic gelation method.
Topics: Acrylic Resins; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Cyclohexanes; Gels; Hypoglycemic Agents; Hypromellose Derivatives; Methylcellulose; Microscopy, Electron, Scanning; Microspheres; Nateglinide; Phenylalanine; Solubility; Spectroscopy, Fourier Transform Infrared | 2013 |
Early diagnosis and treatment of steroid-induced diabetes mellitus in patients with rheumatoid arthritis and other connective tissue diseases.
Topics: Acarbose; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Glucose; Connective Tissue Diseases; Cyclohexanes; Diabetes Mellitus; Early Diagnosis; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Prednisolone; Treatment Outcome | 2014 |
Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
Topics: Adrenergic beta-Antagonists; Aged; Calcium Channel Blockers; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Female; Follow-Up Studies; Glucose Intolerance; Glucose Tolerance Test; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Models, Statistical; Nateglinide; Phenylalanine; Risk Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Clinical predictors of atheroma progression despite optimal glycemic control in early-stage diabetic patients with coronary artery disease: Insight from the DIANA study.
Topics: Blood Glucose; Coronary Angiography; Coronary Artery Disease; Cyclohexanes; Diabetes Mellitus; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inositol; Life Style; Male; Middle Aged; Nateglinide; Phenylalanine; Plaque, Atherosclerotic; Prospective Studies; Risk Factors; Ultrasonography, Interventional | 2014 |
Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR.
Topics: Aged; Cyclohexanes; Diet; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Motor Activity; Nateglinide; Phenylalanine; Placebos; Tetrazoles; Valine; Valsartan | 2014 |
Development of controlled release tablet by optimizing HPMC: consideration of theoretical release and RSM.
Topics: Cyclohexanes; Delayed-Action Preparations; Excipients; Hypoglycemic Agents; Hypromellose Derivatives; Kinetics; Models, Chemical; Nateglinide; Phenylalanine; Tablets | 2014 |
Effects of nateglinide and repaglinide administered intracerebroventricularly on the CA3 hippocampal neuronal cell death and hyperglycemia induced by kainic acid in mice.
Topics: Animals; Blood Glucose; CA3 Region, Hippocampal; Carbamates; Cell Death; Corticosterone; Cyclohexanes; Excitatory Amino Acid Agonists; Hypoglycemic Agents; Infusions, Intraventricular; Insulin; Kainic Acid; Male; Mice; Mice, Inbred ICR; Nateglinide; Neurons; Phenylalanine; Piperidines | 2014 |
Maltodextrin based proniosomes of nateglinide: bioavailability assessment.
Topics: Animals; Biological Availability; Chromatography, High Pressure Liquid; Cyclohexanes; Hypoglycemic Agents; Liposomes; Male; Nateglinide; Phenylalanine; Polysaccharides; Rabbits; Reproducibility of Results | 2014 |
Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions.
Topics: Antihypertensive Agents; Binding, Competitive; Biological Transport; Cyclohexanes; Cyclosporine; Drug Evaluation, Preclinical; Drug Interactions; Estradiol; Gemfibrozil; HEK293 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Kinetics; Liver-Specific Organic Anion Transporter 1; Membrane Transport Modulators; Models, Biological; Nateglinide; Organic Anion Transporters; Phenylalanine; Recombinant Proteins; Rifampin; Sulfonamides; Torsemide | 2015 |
Complex formation with layered double hydroxides for the remediation of hygroscopicity.
Topics: Carbonates; Chlorides; Cyclohexanes; Drug Carriers; Hydroxides; Intercalating Agents; Nateglinide; Nitrates; Phenylalanine; Pravastatin; Wettability | 2015 |
[Prandial glucose regulator and insulin secretagogue; glinide and its combination therapy].
Topics: Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hyperglycemia; Hypoglycemic Agents; Isoindoles; Nateglinide; Phenylalanine | 2015 |
Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial.
Topics: Accelerometry; Actigraphy; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Cardiovascular Diseases; Cohort Studies; Cyclohexanes; Fasting; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Longitudinal Studies; Male; Middle Aged; Motor Activity; Nateglinide; Phenylalanine; Prospective Studies; Regression Analysis; Risk Factors; Risk Reduction Behavior; Valsartan | 2015 |
Co-Amorphous Combination of Nateglinide-Metformin Hydrochloride for Dissolution Enhancement.
Topics: Chemistry, Pharmaceutical; Cyclohexanes; Drug Combinations; Metformin; Nateglinide; Phenylalanine; Solubility; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2016 |
Age-Dependent Onset of Insulin Resistance in Insulin-Resistant Mice.
Topics: Adipose Tissue; Age Factors; Animals; Blood Glucose; Cyclohexanes; Glucose; Glucose Intolerance; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Mice, Inbred Strains; Nateglinide; Obesity; Phenylalanine; Receptor, Insulin; RNA, Messenger | 2015 |
Preparation of polyclonal antibodies for nateglinide (NTG) and development of a sensitive chemiluminescent immunoassay to detect NTG in tablets and serum.
Topics: Antibodies; Blood Chemical Analysis; Chemistry, Pharmaceutical; Cyclohexanes; Immunoassay; Kinetics; Limit of Detection; Luminescent Measurements; Nateglinide; Phenylalanine; Tablets | 2016 |
International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Asia; Australia; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Europe; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Latin America; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Nateglinide; New Zealand; North America; Outcome Assessment, Health Care; Phenylalanine; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; South Africa; Stroke; Valsartan | 2017 |
Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues.
Topics: Area Under Curve; Carbamates; Cyclohexanes; Databases, Factual; Diabetes Mellitus, Type 2; Drug Interactions; Glipizide; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Medical Informatics; Nateglinide; Pharmacoepidemiology; Phenylalanine; Piperidines; Sulfonylurea Compounds | 2017 |
Enhanced dissolution and bioavailability of Nateglinide by microenvironmental pH-regulated ternary solid dispersion: in-vitro and in-vivo evaluation.
Topics: Animals; Biological Availability; Carbonates; Chemistry, Pharmaceutical; Cyclohexanes; Drug Compounding; Drug Liberation; Excipients; Female; Hydrogen-Ion Concentration; Hypoglycemic Agents; Male; Nateglinide; Phenylalanine; Poloxamer; Rats; Rats, Wistar; Solubility | 2017 |
Effect of semicrystalline polymers on self-emulsifying solid dispersions of nateglinide: in vitro and in vivo evaluation.
Topics: Administration, Oral; Animals; Biological Availability; Calorimetry, Differential Scanning; Cyclohexanes; Drug Carriers; Drug Liberation; Emulsions; Nateglinide; Phenylalanine; Poloxamer; Polymers; Rabbits; Solubility; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2018 |
Diabetic Hemichorea-hemiballism after Prompt Improvement in Hyperglycemia.
Topics: Chorea; Cyclohexanes; Diabetes Complications; Dyskinesias; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Linagliptin; Lower Extremity; Magnetic Resonance Imaging; Male; Middle Aged; Nateglinide; Phenylalanine | 2017 |
Helical-Like Assembly of Nateglinide as Coating for Oral Delivery of Insulin and Their Synergistic Prevention of Diabetes Mellitus.
Topics: Animals; Diabetes Mellitus, Experimental; Glycogen Synthase Kinase 3 beta; Humans; Insulin; Insulin Resistance; Mice; Microgels; Nateglinide; Phenylalanine | 2023 |